<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">

<!-- Mirrored from en.wikipedia.org/wiki/C-Met_inhibitor by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 05 May 2022 18:32:08 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
<meta charset="UTF-8"/>
<title>c-Met inhibitor - Wikipedia</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":false,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"d1973400-43db-4109-8134-038532ac3641","wgCSPNonce":false,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"C-Met_inhibitor","wgTitle":"C-Met inhibitor","wgCurRevisionId":1079883091,"wgRevisionId":1079883091,"wgArticleId":33238902,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["All articles with vague or ambiguous time","Vague or ambiguous time from November 2020","Wikipedia articles in need of updating from December 2011","All Wikipedia articles in need of updating","Articles contradicting other articles",
"Articles containing potentially dated statements from 2010","All articles containing potentially dated statements","Articles to be expanded from June 2018","All articles to be expanded","Articles using small message boxes","Articles with incomplete citations from November 2020","All articles with incomplete citations","All pages needing cleanup","Cancer research","Protein kinase inhibitors","Breakthrough therapy","Orphan drugs"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"C-Met_inhibitor","wgRelevantArticleId":33238902,"wgIsProbablyEditable":true,"wgRelevantPageIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgFlaggedRevsParams":{"tags":{"status":{"levels":1}}},"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"wgMFDisplayWikibaseDescriptions":{"search":true,"nearby":true,"watchlist":true,"tagline":false},"wgWMESchemaEditAttemptStepOversample":false,"wgWMEPageLength":30000,
"wgNoticeProject":"wikipedia","wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgPopupsFlags":10,"wgULSCurrentAutonym":"English","wgEditSubmitButtonLabelPublish":true,"wgCentralAuthMobileDomain":false,"wgULSPosition":"interlanguage","wgULSisCompactLinksEnabled":true,"wgWikibaseItemId":"Q5005894"};RLSTATE={"ext.globalCssJs.user.styles":"ready","site.styles":"ready","user.styles":"ready","ext.globalCssJs.user":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.vector.styles.legacy":"ready","jquery.makeCollapsible.styles":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.wikimediaBadges":"ready","ext.uls.interlanguage":"ready","wikibase.client.init":"ready"};RLPAGEMODULES=["ext.cite.ux-enhancements","site","mediawiki.page.ready","jquery.makeCollapsible","mediawiki.toc","https://en.wikipedia.org/wiki/skins.vector.legacy.js","mmv.head","mmv.bootstrap.autostart","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader",
"ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","ext.cx.eventlogging.campaigns","ext.centralNotice.geoIP","ext.centralNotice.startUp","ext.gadget.ReferenceTooltips","ext.gadget.charinsert","ext.gadget.extra-toolbar-buttons","ext.gadget.refToolbar","ext.gadget.switcher","ext.centralauth.centralautologin","ext.popups","ext.uls.compactlinks","ext.uls.interface","ext.growthExperiments.SuggestedEditSession"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1i9g4",function($,jQuery,require,module){mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});});});</script>
<link rel="stylesheet" href="https://en.wikipedia.org/w/load.php?lang=en&amp;modules=ext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cjquery.makeCollapsible.styles%7Cskins.vector.styles.legacy%7Cwikibase.client.init&amp;only=styles&amp;skin=vector"/>
<script async="" src="https://en.wikipedia.org/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=vector"></script>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="https://en.wikipedia.org/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=vector"/>
<meta name="generator" content="MediaWiki 1.39.0-wmf.10"/>
<meta name="referrer" content="origin"/>
<meta name="referrer" content="origin-when-crossorigin"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<meta name="format-detection" content="telephone=no"/>
<meta property="og:title" content="c-Met inhibitor - Wikipedia"/>
<meta property="og:type" content="website"/>
<link rel="preconnect" href="http://upload.wikimedia.org/"/>
<link rel="alternate" media="only screen and (max-width: 720px)" href="http://en.m.wikipedia.org/wiki/C-Met_inhibitor"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit"/>
<link rel="apple-touch-icon" href="https://en.wikipedia.org/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="https://en.wikipedia.org/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="https://en.wikipedia.org/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="http://en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="license" href="https://creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/C-Met_inhibitor"/>
<link rel="dns-prefetch" href="http://meta.wikimedia.org/" />
<link rel="dns-prefetch" href="http://login.wikimedia.org/"/>
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-C-Met_inhibitor rootpage-C-Met_inhibitor skin-vector action-view skin-vector-legacy"><div id="mw-page-base" class="noprint"></div>
<div id="mw-head-base" class="noprint"></div>
<div id="content" class="mw-body" role="main">
	<a id="top"></a>
	<div id="siteNotice"><!-- CentralNotice --></div>
	<div class="mw-indicators">
	</div>
	<h1 id="firstHeading" class="firstHeading mw-first-heading">c-Met inhibitor</h1>
	<div id="bodyContent" class="vector-body">
		<div id="siteSub" class="noprint">From Wikipedia, the free encyclopedia</div>
		<div id="contentSub"></div>
		<div id="contentSub2"></div>
		
		<div id="jump-to-nav"></div>
		<a class="mw-jump-link" href="#mw-head">Jump to navigation</a>
		<a class="mw-jump-link" href="#searchInput">Jump to search</a>
		<div id="mw-content-text" class="mw-body-content mw-content-ltr" lang="en" dir="ltr"><div class="mw-parser-output"><p><b>c-Met inhibitors</b> are a class of <a href="https://en.wikipedia.org/wiki/Small_molecule" title="Small molecule">small molecules</a> that <a href="https://en.wikipedia.org/wiki/Enzyme_inhibitor" title="Enzyme inhibitor">inhibit</a> the enzymatic activity of the <a href="https://en.wikipedia.org/wiki/C-Met" title="C-Met">c-Met</a> <a href="https://en.wikipedia.org/wiki/Tyrosine_kinase" title="Tyrosine kinase">tyrosine kinase</a>, the <a href="https://en.wikipedia.org/wiki/Receptor_(biochemistry)" title="Receptor (biochemistry)">receptor</a> of <a href="https://en.wikipedia.org/wiki/Hepatocyte_growth_factor" title="Hepatocyte growth factor">hepatocyte growth factor/scatter factor</a> (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers.<sup id="cite_ref-pmid21740293_1-0" class="reference"><a href="#cite_note-pmid21740293-1">&#91;1&#93;</a></sup>
</p><p>Many c-Met inhibitors are currently<sup class="noprint Inline-Template" style="white-space:nowrap;">&#91;<i><a href="https://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items" title="Wikipedia:Manual of Style/Dates and numbers"><span title="The time period mentioned near this tag is ambiguous. (November 2020)">when?</span></a></i>&#93;</sup> in <a href="https://en.wikipedia.org/wiki/Clinical_trial" title="Clinical trial">clinical trials</a>. <a href="https://en.wikipedia.org/wiki/Crizotinib" title="Crizotinib">Crizotinib</a><sup id="cite_ref-2" class="reference"><a href="#cite_note-2">&#91;2&#93;</a></sup> and <a href="https://en.wikipedia.org/wiki/Cabozantinib" title="Cabozantinib">cabozantinib</a> were the first to be approved by the <a href="https://en.wikipedia.org/wiki/US_FDA" class="mw-redirect" title="US FDA">U.S. FDA</a>. Crizotinib received accelerated approval in 2011 for the treatment of patients with locally advanced or metastatic <a href="https://en.wikipedia.org/wiki/Non-small-cell_lung_carcinoma" title="Non-small-cell lung carcinoma">non-small cell lung cancer</a>, while cabozantinib was approved in 2012 for the treatment of <a href="https://en.wikipedia.org/wiki/Medullary_thyroid_cancer" title="Medullary thyroid cancer">medullary thyroid cancer</a><sup id="cite_ref-FDA2012_3-0" class="reference"><a href="#cite_note-FDA2012-3">&#91;3&#93;</a></sup> and it has also started clinical trials for the treatment of several other types of cancer.
</p><p>c-Met stimulates cell scattering, invasion, protection from <a href="https://en.wikipedia.org/wiki/Apoptosis" title="Apoptosis">apoptosis</a> and <a href="https://en.wikipedia.org/wiki/Angiogenesis" title="Angiogenesis">angiogenesis</a>.<sup id="cite_ref-Comoglio2008_4-0" class="reference"><a href="#cite_note-Comoglio2008-4">&#91;4&#93;</a></sup> c-Met is a <a href="https://en.wikipedia.org/wiki/Receptor_tyrosine_kinase" title="Receptor tyrosine kinase">receptor tyrosine kinase</a>,<sup id="cite_ref-Maulik2002_5-0" class="reference"><a href="#cite_note-Maulik2002-5">&#91;5&#93;</a></sup> which can cause a wide variety of different cancers, such as <a href="https://en.wikipedia.org/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal</a>, <a href="https://en.wikipedia.org/wiki/Stomach_cancer" title="Stomach cancer">gastric</a> and <a href="https://en.wikipedia.org/wiki/Small-cell_carcinoma" title="Small-cell carcinoma">small cell lung carcinomas</a>, <a href="https://en.wikipedia.org/wiki/Central_nervous_system" title="Central nervous system">central nervous system</a> tumours, as well as several <a href="https://en.wikipedia.org/wiki/Sarcomas" class="mw-redirect" title="Sarcomas">sarcomas</a><sup id="cite_ref-Davis2010_6-0" class="reference"><a href="#cite_note-Davis2010-6">&#91;6&#93;</a></sup> when its activity is dysregulated. Targeting the <a href="https://en.wikipedia.org/wiki/Adenosine_triphosphate" title="Adenosine triphosphate">ATP</a> binding site of c-Met by small <a href="https://en.wikipedia.org/wiki/Molecules" class="mw-redirect" title="Molecules">molecules</a> inhibitors is one strategy for inhibition of the tyrosine kinase.<sup id="cite_ref-Porter2009_7-0" class="reference"><a href="#cite_note-Porter2009-7">&#91;7&#93;</a></sup>
</p>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Introduction"><span class="tocnumber">2</span> <span class="toctext">Introduction</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Structure_and_function"><span class="tocnumber">3</span> <span class="toctext">Structure and function</span></a></li>
<li class="toclevel-1 tocsection-4"><a href="#Development"><span class="tocnumber">4</span> <span class="toctext">Development</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#ATP-competitive_small_molecule_c-Met_inhibitors"><span class="tocnumber">5</span> <span class="toctext">ATP-competitive small molecule c-Met inhibitors</span></a>
<ul>
<li class="toclevel-2 tocsection-6"><a href="#Class_I"><span class="tocnumber">5.1</span> <span class="toctext">Class I</span></a>
<ul>
<li class="toclevel-3 tocsection-7"><a href="#Structure-activity_relationship_of_Class_I_inhibitors"><span class="tocnumber">5.1.1</span> <span class="toctext">Structure-activity relationship of Class I inhibitors</span></a></li>
<li class="toclevel-3 tocsection-8"><a href="#Examples_of_Class_I_inhibitors"><span class="tocnumber">5.1.2</span> <span class="toctext">Examples of Class I inhibitors</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-9"><a href="#Class_II"><span class="tocnumber">5.2</span> <span class="toctext">Class II</span></a>
<ul>
<li class="toclevel-3 tocsection-10"><a href="#Structure-activity_relationship_of_Class_II_inhibitors"><span class="tocnumber">5.2.1</span> <span class="toctext">Structure-activity relationship of Class II inhibitors</span></a></li>
<li class="toclevel-3 tocsection-11"><a href="#Examples_of_Class_II_inhibitors"><span class="tocnumber">5.2.2</span> <span class="toctext">Examples of Class II inhibitors</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-12"><a href="#ATP_non-competitive_small_molecule_c-Met_inhibitors"><span class="tocnumber">6</span> <span class="toctext">ATP non-competitive small molecule c-Met inhibitors</span></a>
<ul>
<li class="toclevel-2 tocsection-13"><a href="#Tivantinib"><span class="tocnumber">6.1</span> <span class="toctext">Tivantinib</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-14"><a href="#Clinical_trials_and_regulatory_approvals"><span class="tocnumber">7</span> <span class="toctext">Clinical trials and regulatory approvals</span></a>
<ul>
<li class="toclevel-2 tocsection-15"><a href="#Status_as_of_2010"><span class="tocnumber">7.1</span> <span class="toctext">Status as of 2010</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Since_2010"><span class="tocnumber">7.2</span> <span class="toctext">Since 2010</span></a></li>
<li class="toclevel-2 tocsection-17"><a href="#Research_on_other_inhibitors"><span class="tocnumber">7.3</span> <span class="toctext">Research on other inhibitors</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-18"><a href="#See_also"><span class="tocnumber">8</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-19"><a href="#External_links"><span class="tocnumber">9</span> <span class="toctext">External links</span></a></li>
<li class="toclevel-1 tocsection-20"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=1" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright"><div class="thumbinner" style="width:202px;"><a href="https://en.wikipedia.org/wiki/File:K252_and_c-met.png" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/1/14/K252_and_c-met.png/200px-K252_and_c-met.png" decoding="async" width="200" height="172" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/14/K252_and_c-met.png/300px-K252_and_c-met.png 1.5x, //upload.wikimedia.org/wikipedia/commons/1/14/K252_and_c-met.png 2x" data-file-width="337" data-file-height="289" /></a>  <div class="thumbcaption"><div class="magnify"><a href="https://en.wikipedia.org/wiki/File:K252_and_c-met.png" class="internal" title="Enlarge"></a></div>Figure 3. K252a, the first small molecule Met inhibitor to be solved in complex with the unphosphorylated Met kinase domain. Two key hydrogen bonds form between the hinge of Met and the pyrralocarbazole.<sup id="cite_ref-Schiering2003_8-0" class="reference"><a href="#cite_note-Schiering2003-8">&#91;8&#93;</a></sup></div></div></div>
<p>Early in the 1980s MET was described as the <a href="https://en.wikipedia.org/wiki/Protein" title="Protein">protein</a> product of a transforming <a href="https://en.wikipedia.org/wiki/Oncogene" title="Oncogene">oncogene</a>.<sup id="cite_ref-Sattler2003_9-0" class="reference"><a href="#cite_note-Sattler2003-9">&#91;9&#93;</a></sup>
<sup id="cite_ref-Porter2010_10-0" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup>
</p>
<div class="thumb tleft"><div class="thumbinner" style="width:202px;"><a href="https://en.wikipedia.org/wiki/File:SU_11274.tif" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/b/b4/SU_11274.tif/lossy-page1-200px-SU_11274.tif.jpg" decoding="async" width="200" height="100" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/SU_11274.tif/lossy-page1-300px-SU_11274.tif.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b4/SU_11274.tif/lossy-page1-400px-SU_11274.tif.jpg 2x" data-file-width="373" data-file-height="187" /></a>  <div class="thumbcaption"><div class="magnify"><a href="https://en.wikipedia.org/wiki/File:SU_11274.tif" class="internal" title="Enlarge"></a></div>Figure 1. SU11274, a first generation c-Met inhibitor (indolin-2-one core in red circle).</div></div></div>
<div class="thumb tleft"><div class="thumbinner" style="width:202px;"><a href="https://en.wikipedia.org/wiki/File:PHA_665752.tif" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/0/06/PHA_665752.tif/lossy-page1-200px-PHA_665752.tif.jpg" decoding="async" width="200" height="72" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/0/06/PHA_665752.tif/lossy-page1-300px-PHA_665752.tif.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/06/PHA_665752.tif/lossy-page1-400px-PHA_665752.tif.jpg 2x" data-file-width="373" data-file-height="135" /></a>  <div class="thumbcaption"><div class="magnify"><a href="https://en.wikipedia.org/wiki/File:PHA_665752.tif" class="internal" title="Enlarge"></a></div>Figure 2. PHA665752, a second-generation c-Met inhibitor.</div></div></div>
<p>Initial attempts to identify ATP-<a href="https://en.wikipedia.org/wiki/Competitive_inhibition" title="Competitive inhibition">competitive</a> c-Met inhibitors in 2002 led to the discovery of <a href="https://en.wikipedia.org/wiki/K252a" title="K252a">K252a</a>, a <a href="https://en.wikipedia.org/wiki/Staurosporine" title="Staurosporine">staurosporine</a>-like inhibitor which blocks c-Met.<sup id="cite_ref-Porter2010_10-1" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup><sup id="cite_ref-Christensen2003_11-0" class="reference"><a href="#cite_note-Christensen2003-11">&#91;11&#93;</a></sup>
K252a was the first structure to be solved in complex with the unphosphorylated MET kinase domain. It forms two <a href="https://en.wikipedia.org/wiki/Hydrogen_bonds" class="mw-redirect" title="Hydrogen bonds">hydrogen bonds</a> between the hinge and pyrralocarbazole subunit.<sup id="cite_ref-Schiering2003_8-1" class="reference"><a href="#cite_note-Schiering2003-8">&#91;8&#93;</a></sup>
</p><p>Later, series of more selective c-Met inhibitors were designed, where an indolin-2-one core (encircled in figure 1) was present in several kinase inhibitors. SU-11274 was evolved by substitution at the 5-position of the indolinone <sup id="cite_ref-Sattler2003_9-1" class="reference"><a href="#cite_note-Sattler2003-9">&#91;9&#93;</a></sup> and by adding a 3,5-dimethyl <a href="https://en.wikipedia.org/wiki/Pyrrole" title="Pyrrole">pyrrole</a> group, PHA-665752 was evolved <sup id="cite_ref-Christensen2003_11-1" class="reference"><a href="#cite_note-Christensen2003-11">&#91;11&#93;</a></sup> – a second-generation inhibitor with better potency and activity.<sup id="cite_ref-Porter2010_10-2" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup>
</p><p>Interest in this field has risen rapidly since 2007 and over 70 patent applications had been published in mid-2009.<sup id="cite_ref-Porter2010_10-3" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup>
</p><p>Intensive efforts have been exerted in the <a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry" title="Pharmaceutical industry">pharmaceutical industry</a> following the acceptance of c-Met as a suitable target for cancer therapy. 20 crystal structures with and without <a href="https://en.wikipedia.org/wiki/Ligands" class="mw-redirect" title="Ligands">ligands</a> have been published and in 2010 nearly a dozen small molecule c-Met inhibitors have been tested clinically.<sup id="cite_ref-Underiner2010_12-0" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Introduction">Introduction</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=2" title="Edit section: Introduction">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Receptor tyrosine kinases (RTKs) are a vital element in regulating many <a href="https://en.wikipedia.org/wiki/Intracellular" class="mw-redirect" title="Intracellular">intracellular</a> signal transduction pathways.<sup id="cite_ref-Sattler2009_13-0" class="reference"><a href="#cite_note-Sattler2009-13">&#91;13&#93;</a></sup>
Met tyrosine kinase is the receptor for <a href="https://en.wikipedia.org/wiki/Hepatocyte_growth_factor" title="Hepatocyte growth factor">hepatocyte growth factor</a> (HGF), also known as scatter factor (SF). HGF is mostly expressed on <a href="https://en.wikipedia.org/wiki/Epithelial_cells" class="mw-redirect" title="Epithelial cells">epithelial cells</a> and <a href="https://en.wikipedia.org/wiki/Mesenchymal_cells" class="mw-redirect" title="Mesenchymal cells">mesenchymal cells</a>, for example smooth muscle cells and <a href="https://en.wikipedia.org/wiki/Fibroblasts" class="mw-redirect" title="Fibroblasts">fibroblasts</a>).<sup id="cite_ref-Porter2010_10-4" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup><sup id="cite_ref-Christensen2003_11-2" class="reference"><a href="#cite_note-Christensen2003-11">&#91;11&#93;</a></sup> HGF is normally active in wound healing, <a href="https://en.wikipedia.org/wiki/Liver" title="Liver">liver</a> regeneration, <a href="https://en.wikipedia.org/wiki/Embryo" title="Embryo">embryo</a> and normal <a href="https://en.wikipedia.org/wiki/Mammalian" class="mw-redirect" title="Mammalian">mammalian</a> development,<sup id="cite_ref-Porter2010_10-5" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup> organ <a href="https://en.wikipedia.org/wiki/Morphogenesis" title="Morphogenesis">morphogenesis</a>.<sup id="cite_ref-Christensen2003_11-3" class="reference"><a href="#cite_note-Christensen2003-11">&#91;11&#93;</a></sup>
</p><p>c-Met dysregulation can be due to overexpression, gene amplification, <a href="https://en.wikipedia.org/wiki/Mutation" title="Mutation">mutation</a>, a ligand-dependent auto- or paracrine loop or an untimely activation of RTK.<sup id="cite_ref-Porter2010_10-6" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup><sup id="cite_ref-Sattler2009_13-1" class="reference"><a href="#cite_note-Sattler2009-13">&#91;13&#93;</a></sup> All these factors affect the survival of cells, their <a href="https://en.wikipedia.org/wiki/Cell_growth" title="Cell growth">proliferation</a> and motility. They also lead to cancers and resistance to therapies which aim to treat them.<sup id="cite_ref-Sattler2009_13-2" class="reference"><a href="#cite_note-Sattler2009-13">&#91;13&#93;</a></sup> Patients with aberrant c-Met activity usually have a poor <a href="https://en.wikipedia.org/wiki/Prognosis" title="Prognosis">prognosis</a>, aggressive disease, increased <a href="https://en.wikipedia.org/wiki/Metastasis" title="Metastasis">metastasis</a> and shortened survival.<sup id="cite_ref-Porter2010_10-7" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup> This is why targeting the HGF/c-MET signalling pathway has been untaken as a treatment for cancer,<sup id="cite_ref-Porter2010_10-8" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup><sup id="cite_ref-Sattler2009_13-3" class="reference"><a href="#cite_note-Sattler2009-13">&#91;13&#93;</a></sup> and several different therapeutic approaches are being clinically tested. A variety of approaches have been used to target c-Met, each focusing on one of the serial steps that regulate c-Met activation by <a href="https://en.wikipedia.org/wiki/Antibodies" class="mw-redirect" title="Antibodies">antibodies</a>, peptide <a href="https://en.wikipedia.org/wiki/Agonists" class="mw-redirect" title="Agonists">agonists</a>,<sup id="cite_ref-Comoglio2008_4-1" class="reference"><a href="#cite_note-Comoglio2008-4">&#91;4&#93;</a></sup><sup id="cite_ref-Porter2010_10-9" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup> decoy receptors and other biologic inhibitors<sup id="cite_ref-Christensen2005_14-0" class="reference"><a href="#cite_note-Christensen2005-14">&#91;14&#93;</a></sup>
or small molecules inhibitors.<sup id="cite_ref-Porter2010_10-10" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Structure_and_function">Structure and function</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=3" title="Edit section: Structure and function">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright"><div class="thumbinner" style="width:452px;"><a href="https://en.wikipedia.org/wiki/File:RTK_scematic_labelled.tif" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/5/53/RTK_scematic_labelled.tif/lossy-page1-450px-RTK_scematic_labelled.tif.jpg" decoding="async" width="450" height="366" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/5/53/RTK_scematic_labelled.tif/lossy-page1-675px-RTK_scematic_labelled.tif.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/53/RTK_scematic_labelled.tif/lossy-page1-900px-RTK_scematic_labelled.tif.jpg 2x" data-file-width="778" data-file-height="633" /></a>  <div class="thumbcaption"><div class="magnify"><a href="https://en.wikipedia.org/wiki/File:RTK_scematic_labelled.tif" class="internal" title="Enlarge"></a></div>Figure 4. Schematic structure of some Met inhibitory possibilities: Antibodies and antagonists (such as NK4) bind to the extracellular domain. Met fragments of the extracellular domain can also bind to HGF and act as a decoy Met. Small molecule inhibitors bind to the intracellular Met kinase. Functional domains of Met: P encircled (Phosphate group), S-S (<a href="https://en.wikipedia.org/wiki/Disulfide_bond" class="mw-redirect" title="Disulfide bond">disulfide bond</a>), Sema domain (Semaphorin-like), PSI (Plexins, Semaphorins, Integrins), IPT domain (Immunoglobulin-like, Plexins, Transcription factors) and PTK (Protein Tyrosine Kinase).<sup id="cite_ref-Knudsen2008_15-0" class="reference"><a href="#cite_note-Knudsen2008-15">&#91;15&#93;</a></sup></div></div></div>
<div class="thumb tright"><div class="thumbinner" style="width:302px;"><a href="https://en.wikipedia.org/wiki/File:RTK_domain.jpg" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/4/49/RTK_domain.jpg/300px-RTK_domain.jpg" decoding="async" width="300" height="190" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/49/RTK_domain.jpg/450px-RTK_domain.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/4/49/RTK_domain.jpg/600px-RTK_domain.jpg 2x" data-file-width="758" data-file-height="481" /></a>  <div class="thumbcaption"><div class="magnify"><a href="https://en.wikipedia.org/wiki/File:RTK_domain.jpg" class="internal" title="Enlarge"></a></div>Figure 5. The topographical features of the Met ATP binding site. A: Tyrosine in the <a href="https://en.wikipedia.org/wiki/Activation_loop" class="mw-redirect" title="Activation loop">activation loop</a>, B: Hydrophobic sub-pocket C: Central hydrophobic region, D: Hinge region, E: Hydrophobic sub-pocket.<sup id="cite_ref-Bottaro2011_16-0" class="reference"><a href="#cite_note-Bottaro2011-16">&#91;16&#93;</a></sup></div></div></div>
<p>The c-Met RTK subfamily is different in structure to many other RTK families: The mature form has an extracellular α-chain (50kDa) and a transmembrane β-chain (140kDa) that are linked together by a disulfide bond. The beta chain contains the intracellular tyrosine kinase domain and a tail on the C-terminal which is vital for the docking of <a href="https://en.wikipedia.org/wiki/Enzyme_substrate" class="mw-redirect" title="Enzyme substrate">substrates</a> and downstream signalling.<sup id="cite_ref-Porter2010_10-11" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup>
<sup id="cite_ref-Liu2010_17-0" class="reference"><a href="#cite_note-Liu2010-17">&#91;17&#93;</a></sup>
</p><p>HGF is the natural high-affinity ligand for Met.<sup id="cite_ref-Porter2010_10-12" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup><sup id="cite_ref-Christensen2003_11-4" class="reference"><a href="#cite_note-Christensen2003-11">&#91;11&#93;</a></sup><sup id="cite_ref-Liu2010_17-1" class="reference"><a href="#cite_note-Liu2010-17">&#91;17&#93;</a></sup> Its N-terminal region binds to Met and receptor dimerization as well as <a href="https://en.wikipedia.org/wiki/Autophosphorylation" title="Autophosphorylation">autophosphorylation</a> of two tyrosines occur in the <a href="https://en.wikipedia.org/wiki/Activation_loop" class="mw-redirect" title="Activation loop">activation loop</a> (A-loop) in the kinase domain of Met.<sup id="cite_ref-Porter2010_10-13" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup>
</p><p><a href="https://en.wikipedia.org/wiki/Phosphorylation" title="Phosphorylation">Phosphorylation</a> occurs in tyrosines close to the C-terminus, creating a multi-functional docking site<sup id="cite_ref-Porter2010_10-14" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup><sup id="cite_ref-Kung2008_18-0" class="reference"><a href="#cite_note-Kung2008-18">&#91;18&#93;</a></sup>
which recruits adaptor proteins and leads to downstream signalling. The signaling is mediated by Ras/Mapk, PI3K/Akt, c-Src and STAT3/5 and include cell proliferation, reduced apoptosis, altered <a href="https://en.wikipedia.org/wiki/Cytoskeleton" title="Cytoskeleton">cytoskeletal</a> function and more.
</p><p>The kinase domain usually consists of a bi-lobed structure, where the lobes are connected with a hinge region, adjacent to the very conserved ATP binding site.<sup id="cite_ref-Porter2010_10-15" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Development">Development</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=4" title="Edit section: Development">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Using information from the co-crystal structure of PHA-66752 and c-Met, the selective inhibitor PF-2341066 was designed. It was undergoing Phase I/II clinical trials in 2010. Changing a series of 4-phenoxyquinoline compounds with an <a href="https://en.wikipedia.org/wiki/Acyl" class="mw-redirect" title="Acyl">acyl</a> <a href="https://en.wikipedia.org/wiki/Thiourea" title="Thiourea">thiourea</a> group led to compounds with c-Met activity, e.g. <a href="https://en.wikipedia.org/wiki/Quinoline" title="Quinoline">quinoline</a>.<sup id="cite_ref-Porter2010_10-16" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup> This was a key step in the progress of c-Met inhibitor development in that the acyl binding gives the terminal aryl group the ability to penetrate a deep <a href="https://en.wikipedia.org/wiki/Hydrophobe" title="Hydrophobe">hydrophobic</a> pocket and so it enhances the potency of the compounds. Alternatives to the acyl thiourea linkage have been found, which have a <a href="https://en.wikipedia.org/wiki/Pyrimidone" title="Pyrimidone">pyrimidone</a> group, as in AM7.<sup id="cite_ref-Bellon2008_19-0" class="reference"><a href="#cite_note-Bellon2008-19">&#91;19&#93;</a></sup>
</p><p>AM7 and SU11274 offered the first proof that relatively selective c-Met inhibitors could be identified and that the inhibition leads to an anti-tumour effect <a href="https://en.wikipedia.org/wiki/In_vivo" title="In vivo">in vivo</a>. When the co-crystal structures of AM7 and SU11274 with c-Met were compared, they were found to be different: SU-11274 binds adjacent to the hinge region with a U-shaped conformation; but AM7 binds to c-Met in an extended conformation which spans the area from the hinge region to the C-helix. It then binds in a hydrophobic pocket. c-Met assumes an inactive, unphosphorylated conformation with AM7, which can bind to both phosphorylated and unphosphorylated conformations of the kinase.<sup id="cite_ref-Dussault2009_20-0" class="reference"><a href="#cite_note-Dussault2009-20">&#91;20&#93;</a></sup>
</p><p>Due to these two different types of binding, small molecule Met inhibitors have been divided into two classes; class I (SU-11274-like) and class II (AM7-like).<sup id="cite_ref-Dussault2009_20-1" class="reference"><a href="#cite_note-Dussault2009-20">&#91;20&#93;</a></sup> 
There is however another type of small-molecule inhibitors, which does not fit into either of the two classes; a <a href="https://en.wikipedia.org/wiki/Non-competitive_inhibition" title="Non-competitive inhibition">non-competitive</a> ATP inhibitor that binds in a different way to the other two.<sup id="cite_ref-Eathiraj2011_21-0" class="reference"><a href="#cite_note-Eathiraj2011-21">&#91;21&#93;</a></sup>
</p><p>The small molecule inhibitors vary in selectivity, are either very specific or have a broad selectivity. They are either ATP competitive or non-competitive.<sup id="cite_ref-Underiner2010_12-1" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="ATP-competitive_small_molecule_c-Met_inhibitors">ATP-competitive small molecule c-Met inhibitors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=5" title="Edit section: ATP-competitive small molecule c-Met inhibitors">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Even though the two classes are structurally different, they do share some properties: They both bind at the kinase hinge region (although they occupy different parts of the c-Met active site<sup id="cite_ref-Dussault2009_20-2" class="reference"><a href="#cite_note-Dussault2009-20">&#91;20&#93;</a></sup>) and they all aim to mimic the <a href="https://en.wikipedia.org/wiki/Purine" title="Purine">purine</a> of ATP. BMS-777607 and PF-02341066 have a 2-amino-pyridine group, AMG-458 has a <a href="https://en.wikipedia.org/wiki/Quinoline" title="Quinoline">quinoline</a> group and MK-2461 has a tricyclic aromatic group.<sup id="cite_ref-Allen2011_22-0" class="reference"><a href="#cite_note-Allen2011-22">&#91;22&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Class_I">Class I</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=6" title="Edit section: Class I">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Class I inhibitors have many different structures,<sup id="cite_ref-Underiner2010_12-2" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup> are relatively selective and have a U-shaped conformation<sup id="cite_ref-Porter2010_10-17" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup> and binds to the <a href="https://en.wikipedia.org/wiki/Activation_loop" class="mw-redirect" title="Activation loop">activation loop</a> of c-Met.<sup id="cite_ref-Underiner2010_12-3" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Structure-activity_relationship_of_Class_I_inhibitors">Structure-activity relationship of Class I inhibitors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=7" title="Edit section: Structure-activity relationship of Class I inhibitors">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<div class="thumb tright"><div class="thumbinner" style="width:302px;"><a href="https://en.wikipedia.org/wiki/File:Class_I_c-met_inhibitors_analogs.tif" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/3/35/Class_I_c-met_inhibitors_analogs.tif/lossy-page1-300px-Class_I_c-met_inhibitors_analogs.tif.jpg" decoding="async" width="300" height="248" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/3/35/Class_I_c-met_inhibitors_analogs.tif/lossy-page1-450px-Class_I_c-met_inhibitors_analogs.tif.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/35/Class_I_c-met_inhibitors_analogs.tif/lossy-page1-600px-Class_I_c-met_inhibitors_analogs.tif.jpg 2x" data-file-width="564" data-file-height="467" /></a>  <div class="thumbcaption"><div class="magnify"><a href="https://en.wikipedia.org/wiki/File:Class_I_c-met_inhibitors_analogs.tif" class="internal" title="Enlarge"></a></div>Figure 6. SAR of class I Met inhibitors with various substitution groups. Ar symbolizes an aromatic group (in this figure, from left to right: quinoline, azaindole, benzothiazide, benzyl groups (with various R groups, such as -OH) and methoxyphenyl)). X symbolizes the linker between the core and the aryl group (from left to right: Methyl, difluoro methyl, methoxy, amino and sulfur groups). R1 symbolizes the various groups which were added onto C-7 (from top to bottom: N-linked chlorophenol, N-hydroxyethyl pyrazole and pyrazole). Atoms in positions 1, 5, 8 and 9 in many of the tested analogs were either C or N atoms.<sup id="cite_ref-Underiner2010_12-4" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup></div></div></div>
<p>A series of triazolotriazines was discovered, which showed great promise as a c-MET inhibitors. <a href="https://en.wikipedia.org/wiki/Structure_activity_relationship" class="mw-redirect" title="Structure activity relationship">Structure activity relationship</a> (SAR) implies the necessity of an <a href="https://en.wikipedia.org/wiki/Aryl" title="Aryl">aryl</a> group linked to the <a href="https://en.wikipedia.org/wiki/Triazine" title="Triazine">triazine</a> ring and an appropriate hydrogen bond acceptor (e.g. hydroxyl group) attached to the pendant <a href="https://en.wikipedia.org/wiki/Benzyl" class="mw-redirect" title="Benzyl">benzyl</a> ring but it seems like the <a href="https://en.wikipedia.org/wiki/Phenol" title="Phenol">phenol</a> acts as a hinge binder (with Met1160) and that the <a href="https://en.wikipedia.org/wiki/Triazine" title="Triazine">triazine</a> interacts with Tyr1230.<sup id="cite_ref-Underiner2010_12-5" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
A number of similar analogues were found and assayed. Structurally similar series of c-Met inhibitors in which a phenolic hinge binding element was linked to an arylamino-triazolopyridazine or aryl-triazolothiapyridazine. One-atom linker was more efficient than a two-atom linker and that substitution at the benzylic position seemed to be tolerated. Compounds with <a href="https://en.wikipedia.org/wiki/Heterocyclic_compound" title="Heterocyclic compound">heterocyclic</a> hinge binding elements (quinoline, <a href="https://en.wikipedia.org/wiki/Pyridine" title="Pyridine">pyridine</a>, azaindole) linked to fused, nitrogen-dense heteroaromatics (triazolopyridazines, triazolopyrazines and triazolotriazines) have been described.<sup id="cite_ref-Underiner2010_12-6" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup> 
See figure 4 for details.<sup id="cite_ref-Underiner2010_12-7" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Examples_of_Class_I_inhibitors">Examples of Class I inhibitors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=8" title="Edit section: Examples of Class I inhibitors">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="https://en.wikipedia.org/w/index.php?title=JNJ-38877605&amp;action=edit&amp;redlink=1" class="new" title="JNJ-38877605 (page does not exist)">JNJ-38877605</a>, which contains a difluoro methyl linker and a <a href="https://en.wikipedia.org/wiki/Bioavailability" title="Bioavailability">bioavailable</a> quinoline group, was undergoing clinical trials of Phase I for advanced and refractory solid tumours in 2010.<sup id="cite_ref-Underiner2010_12-8" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup> <sup class="noprint Inline-Template" style="margin-left:0.1em; white-space:nowrap;">&#91;<i><a href="https://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items" title="Wikipedia:Manual of Style/Dates and numbers"><span title="The text near this tag is dated. (December 2011)">needs update</span></a></i>&#93;</sup>
</p><p><a href="https://en.wikipedia.org/w/index.php?title=PF-04217903&amp;action=edit&amp;redlink=1" class="new" title="PF-04217903 (page does not exist)">PF-04217903</a>, an ATP-competitive and exceptionally selective compound, has an N-hydroxyethyl pyrazole group tethered to C-7 of the <a href="https://en.wikipedia.org/w/index.php?title=Triazolopyrazine&amp;action=edit&amp;redlink=1" class="new" title="Triazolopyrazine (page does not exist)">triazolopyrazine</a>. It was undergoing phase I clinical trials in 2010.<sup id="cite_ref-Underiner2010_12-9" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup> <sup class="noprint Inline-Template" style="margin-left:0.1em; white-space:nowrap;">&#91;<i><a href="https://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items" title="Wikipedia:Manual of Style/Dates and numbers"><span title="The text near this tag is dated. (December 2011)">needs update</span></a></i>&#93;</sup>
</p>
<div class="thumb tleft"><div class="thumbinner" style="width:152px;"><a href="https://en.wikipedia.org/wiki/File:MK2461.tif" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/0/06/MK2461.tif/lossy-page1-150px-MK2461.tif.jpg" decoding="async" width="150" height="101" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/0/06/MK2461.tif/lossy-page1-225px-MK2461.tif.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/06/MK2461.tif/lossy-page1-300px-MK2461.tif.jpg 2x" data-file-width="325" data-file-height="218" /></a>  <div class="thumbcaption"><div class="magnify"><a href="https://en.wikipedia.org/wiki/File:MK2461.tif" class="internal" title="Enlarge"></a></div>Figure 7. MK2461, a unique c-Met inhibitor</div></div></div>
<p>The SAR of the unique kinase inhibitor scaffold with powerful c-Met inhibitory activity, <a href="https://en.wikipedia.org/w/index.php?title=MK-2461&amp;action=edit&amp;redlink=1" class="new" title="MK-2461 (page does not exist)">MK-2461</a>, has been explored.<sup id="cite_ref-Katz2011_23-0" class="reference"><a href="#cite_note-Katz2011-23">&#91;23&#93;</a></sup>
The pyridine nitrogen is necessary for inhibition activity and central ring saturation reduced potency.<sup id="cite_ref-Underiner2010_12-10" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup> Planarity of the molecule has proven to be essential for maximum potency.<sup id="cite_ref-Katz2011_23-1" class="reference"><a href="#cite_note-Katz2011-23">&#91;23&#93;</a></sup> Cyclic ethers balance acceptable cell-based activities and <a href="https://en.wikipedia.org/wiki/Pharmacokinetics" title="Pharmacokinetics">pharmacokinetic</a> characteristics. The following elements are thought to be key in the optimization process:
</p><p>1) <a href="https://en.wikipedia.org/wiki/Aryl" title="Aryl">Aryl</a> groups at the 7-position, as if to maximize hydrophobic packing and planarity,
</p><p>2) The tight SAR upon the addition of a <a href="https://en.wikipedia.org/wiki/Sulfonamide_(chemistry)" class="mw-redirect" title="Sulfonamide (chemistry)">sulfonamide</a> group and
</p><p>3) The relatively flat SAR of solvent-exposed groups.
</p><p>Often, oncogenic mutations of c-Met cause a resistance to small molecule inhibitors. An MK-2461 analog was therefore tested against a variety of c-Met mutants but proved to be no less potent against them. This gives the molecule a big advantage as a treatment for tumours caused by c-Met dysregulation.<sup id="cite_ref-Katz2011_23-2" class="reference"><a href="#cite_note-Katz2011-23">&#91;23&#93;</a></sup> MK-2461 was undergoing phase I dose escalation trials in 2010.<sup id="cite_ref-Underiner2010_12-11" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup> <sup class="noprint Inline-Template" style="margin-left:0.1em; white-space:nowrap;">&#91;<i><a href="https://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items" title="Wikipedia:Manual of Style/Dates and numbers"><span title="The text near this tag is dated. (December 2011)">needs update</span></a></i>&#93;</sup>
</p>
<h3><span class="mw-headline" id="Class_II">Class II</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=9" title="Edit section: Class II">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright"><div class="thumbinner" style="width:302px;"><a href="https://en.wikipedia.org/wiki/File:Class_II_c-met_inhibitors_analogs.tif" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Class_II_c-met_inhibitors_analogs.tif/lossy-page1-300px-Class_II_c-met_inhibitors_analogs.tif.jpg" decoding="async" width="300" height="221" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Class_II_c-met_inhibitors_analogs.tif/lossy-page1-450px-Class_II_c-met_inhibitors_analogs.tif.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Class_II_c-met_inhibitors_analogs.tif/lossy-page1-600px-Class_II_c-met_inhibitors_analogs.tif.jpg 2x" data-file-width="851" data-file-height="626" /></a>  <div class="thumbcaption"><div class="magnify"><a href="https://en.wikipedia.org/wiki/File:Class_II_c-met_inhibitors_analogs.tif" class="internal" title="Enlarge"></a></div>Figure 8. A common scaffold for class II Met inhibitors. Atoms in positions F, E, 6 and 3 in many of the tested analogs were either C, C-F or N groups. The O atom of the amide may be substituted for an S atom. The R groups represent some of the groups that were tested against MET with various substitution groups (Left side from top to bottom: Amide, chlorine, aryl oxy qinoline groups, methoxy phenyl and pyrrolotriazines with a terminal amine group. Right side from top to bottom: Fluorophenyl malonamide with a cyclopropyl group, hydroxy methyl phenyl pyrazolone, ethoxy fluorophenyl pyridone and fluorophenyl oxalamide).A: The R3 group lodges into the hydrophobic pocket of c-MET, B: The pyridine group binds to the hinge region and C: The R2 group usually binds to the ribose pocket where the ribose of ATP normally binds.<sup id="cite_ref-Underiner2010_12-12" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup></div></div></div>
<p>Class II inhibitors are usually not as selective as those of class I.<sup id="cite_ref-Porter2010_10-18" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup> <a href="https://en.wikipedia.org/wiki/Urea" title="Urea">Urea</a> groups are also a common feature of class II inhibitors, either in cyclic or acyclic forms. Class II of inhibitors contains a number of different molecules, a common scaffold of which can be seen in figure 4.<sup id="cite_ref-Underiner2010_12-13" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Structure-activity_relationship_of_Class_II_inhibitors">Structure-activity relationship of Class II inhibitors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=10" title="Edit section: Structure-activity relationship of Class II inhibitors">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Series of quinoline c-Met inhibitors with an acylthiourea linkage have been explored. Multiple series of analogs have been found with alternative hinge binding groups (e.g. replacement of the quinoline group), replacement of the <a href="https://en.wikipedia.org/wiki/Thiourea" title="Thiourea">thiourea</a> linkage (e.g. malonamide, oxalamide, pyrazolones) and constraining of the acyclic acylthiourea structure fragment with various aromatic heterocycles. Further refinement included the blocking of the p-position of the pendant phenyl ring with a <a href="https://en.wikipedia.org/wiki/Fluorine" title="Fluorine">fluorine</a> atom.<sup id="cite_ref-Underiner2010_12-14" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
Example of interactions between c-Met and a small molecules (marked in a red circle) of class II are as follows: The scaffold of c-Met lodges into the ATP pocket by three key hydrogen bonds, the terminal <a href="https://en.wikipedia.org/wiki/Amine" title="Amine">amine</a> interacts with the <a href="https://en.wikipedia.org/wiki/Ribose" title="Ribose">ribose</a> pocket (of ATP), the terminal 4-fluorophenyl group is oriented in a hydrophobic pocket and pyrrolotriazine plays the role of the hinge-binding group.<sup id="cite_ref-Underiner2010_12-15" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Examples_of_Class_II_inhibitors">Examples of Class II inhibitors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=11" title="Edit section: Examples of Class II inhibitors">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>In phase II clinical trials, <a href="https://en.wikipedia.org/wiki/Foretinib" title="Foretinib">GSK 1363089</a> (XL880, foretinib) was well tolerated. It led to slight regressions or stable disease in patients with papillary renal carcinoma and poorly differentiated gastric cancer.<sup id="cite_ref-Underiner2010_12-16" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
</p><p><a href="https://en.wikipedia.org/w/index.php?title=AMG_458&amp;action=edit&amp;redlink=1" class="new" title="AMG 458 (page does not exist)">AMG 458</a> is a potent small molecule c-MET inhibitor which proved to have more than a 100-fold selectivity for c-MET across a panel of 55 kinases. Also, AMG 458 was 100% bioavailable across species and the intrinsic <a href="https://en.wikipedia.org/wiki/Half-life" title="Half-life">half-life</a> increased with higher mammals.<sup id="cite_ref-Underiner2010_12-17" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="ATP_non-competitive_small_molecule_c-Met_inhibitors">ATP non-competitive small molecule c-Met inhibitors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=12" title="Edit section: ATP non-competitive small molecule c-Met inhibitors">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Tivantinib">Tivantinib</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=13" title="Edit section: Tivantinib">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright"><div class="thumbinner" style="width:102px;"><a href="https://en.wikipedia.org/wiki/File:Tivantinib.svg" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/b/ba/Tivantinib.svg/100px-Tivantinib.svg.png" decoding="async" width="100" height="142" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/ba/Tivantinib.svg/150px-Tivantinib.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/ba/Tivantinib.svg/200px-Tivantinib.svg.png 2x" data-file-width="323" data-file-height="460" /></a>  <div class="thumbcaption"><div class="magnify"><a href="https://en.wikipedia.org/wiki/File:Tivantinib.svg" class="internal" title="Enlarge"></a></div><a href="https://en.wikipedia.org/wiki/Tivantinib" title="Tivantinib">Tivantinib</a> (ARQ197), a c-Met inhibitor</div></div></div>
<table class="box-Contradicts_other plainlinks metadata ambox ambox-content" role="presentation"><tbody><tr><td class="mbox-image"><div style="width:52px"><img alt="Accuracy dispute" src="http://upload.wikimedia.org/wikipedia/commons/thumb/2/2e/Ambox_contradict.svg/40px-Ambox_contradict.svg.png" decoding="async" title="Accuracy dispute" width="40" height="40" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/2/2e/Ambox_contradict.svg/60px-Ambox_contradict.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/2e/Ambox_contradict.svg/80px-Ambox_contradict.svg.png 2x" data-file-width="620" data-file-height="620" /></div></td><td class="mbox-text"><div class="mbox-text-span">This article <b>appears to contradict the article <a href="https://en.wikipedia.org/wiki/Tivantinib" title="Tivantinib">Tivantinib</a></b>.<span class="hide-when-compact"> Please see discussion on the linked <a href="https://en.wikipedia.org/wiki/Talk:C-Met_inhibitor" title="Talk:C-Met inhibitor">talk page</a>.</span>  <span class="date-container"><i>(<span class="date">November 2015</span>)</i></span><span class="hide-when-compact"><i> (<small><a href="https://en.wikipedia.org/wiki/Help:Maintenance_template_removal" title="Help:Maintenance template removal">Learn how and when to remove this template message</a></small>)</i></span></div></td></tr></tbody></table>
<p><a href="https://en.wikipedia.org/wiki/Tivantinib" title="Tivantinib">Tivantinib</a> (ARQ197) is a selective, orally bioavailable,<sup id="cite_ref-Liu2010_17-2" class="reference"><a href="#cite_note-Liu2010-17">&#91;17&#93;</a></sup><sup id="cite_ref-Eathiraj2011_21-1" class="reference"><a href="#cite_note-Eathiraj2011-21">&#91;21&#93;</a></sup> clinically advanced low-molecular weight and well-tolerated c-MET inhibitor, which is currently<sup class="noprint Inline-Template" style="white-space:nowrap;">&#91;<i><a href="https://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items" title="Wikipedia:Manual of Style/Dates and numbers"><span title="The time period mentioned near this tag is ambiguous. (November 2020)">when?</span></a></i>&#93;</sup> in Phase III clinical trials in <a href="https://en.wikipedia.org/wiki/Non-small_cell_lung_carcinoma" class="mw-redirect" title="Non-small cell lung carcinoma">non-small cell lung cancer</a> patients.<sup id="cite_ref-Eathiraj2011_21-2" class="reference"><a href="#cite_note-Eathiraj2011-21">&#91;21&#93;</a></sup> ARQ197 is a non-ATP competitive c-MET autophosphorylation inhibitor with a high selectivity for the unphosphorylated conformation of the kinase.<sup id="cite_ref-Liu2010_17-3" class="reference"><a href="#cite_note-Liu2010-17">&#91;17&#93;</a></sup><sup id="cite_ref-Eathiraj2011_21-3" class="reference"><a href="#cite_note-Eathiraj2011-21">&#91;21&#93;</a></sup> Tivantinib cuts off the interactions between the key <a href="https://en.wikipedia.org/wiki/Catalysis" title="Catalysis">catalytic</a> residues.<sup id="cite_ref-Eathiraj2011_21-4" class="reference"><a href="#cite_note-Eathiraj2011-21">&#91;21&#93;</a></sup>
The structure of tivantinib in complex with the c-Met kinase domain shows that the inhibitor binds a conformation that is distinct from published kinase structures. Tivantinib strongly inhibits c-Met autoactivation by selectively targeting the inactive form of the kinase between the N- and C- lobes and occupies the ATP binding site.<sup id="cite_ref-Eathiraj2011_21-5" class="reference"><a href="#cite_note-Eathiraj2011-21">&#91;21&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Clinical_trials_and_regulatory_approvals">Clinical trials and regulatory approvals</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=14" title="Edit section: Clinical trials and regulatory approvals">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Status_as_of_2010">Status as of 2010</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=15" title="Edit section: Status as of 2010">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Since the discovery of Met and HGF, much research interest has focused on their roles in cancer. The Met pathway is one of the most frequently dysregulated pathways in human cancer.<sup id="cite_ref-Liu2010_17-4" class="reference"><a href="#cite_note-Liu2010-17">&#91;17&#93;</a></sup> 
Increased understanding of the binding modes and structural design brings us closer to the use of other protein interactions and binding pockets, creating inhibitors with alternative structures and optimized profiles.<sup id="cite_ref-Porter2010_10-19" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup>
</p>
<style data-mw-deduplicate="TemplateStyles:r978413945/mw-parser-output/.tmulti">.mw-parser-output .tmulti .thumbinner{display:flex;flex-direction:column}.mw-parser-output .tmulti .trow{display:flex;flex-direction:row;clear:left;flex-wrap:wrap;width:100%;box-sizing:border-box}.mw-parser-output .tmulti .tsingle{margin:1px;float:left}.mw-parser-output .tmulti .theader{clear:both;font-weight:bold;text-align:center;align-self:center;background-color:transparent;width:100%}.mw-parser-output .tmulti .thumbcaption{background-color:transparent}.mw-parser-output .tmulti .text-align-left{text-align:left}.mw-parser-output .tmulti .text-align-right{text-align:right}.mw-parser-output .tmulti .text-align-center{text-align:center}@media all and (max-width:720px){.mw-parser-output .tmulti .thumbinner{width:100%!important;box-sizing:border-box;max-width:none!important;align-items:center}.mw-parser-output .tmulti .trow{justify-content:center}.mw-parser-output .tmulti .tsingle{float:none!important;max-width:100%!important;box-sizing:border-box;text-align:center}.mw-parser-output .tmulti .tsingle .thumbcaption{text-align:left}.mw-parser-output .tmulti .trow>.thumbcaption{text-align:center}}</style><div class="thumb tmulti tright"><div class="thumbinner" style="width:617px;max-width:617px"><div class="trow"><div class="theader"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold">Table 1. Examples of small molecule c-Met inhibitors in clinical trials (2010).<sup id="cite_ref-Underiner2010_12-18" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup></span></div></div><div class="trow"><div class="tsingle" style="width:615px;max-width:615px"><div class="thumbimage"><a href="https://en.wikipedia.org/wiki/File:Current_status_in_c-met_inhibitors_2010.tif" class="image"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/6/6d/Current_status_in_c-met_inhibitors_2010.tif/lossy-page1-613px-Current_status_in_c-met_inhibitors_2010.tif.jpg" decoding="async" width="613" height="500" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/6d/Current_status_in_c-met_inhibitors_2010.tif/lossy-page1-920px-Current_status_in_c-met_inhibitors_2010.tif.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/6d/Current_status_in_c-met_inhibitors_2010.tif/lossy-page1-1226px-Current_status_in_c-met_inhibitors_2010.tif.jpg 2x" data-file-width="613" data-file-height="500" /></a></div><div class="thumbcaption">SND: structure not disclosed; RON: Recepteur d'origine nantais ALK: <a href="https://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase" title="Anaplastic lymphoma kinase">Anaplastic lymphoma kinase</a>; <a href="https://en.wikipedia.org/wiki/VEGF_receptor" title="VEGF receptor">VEGFR2</a>: Vascular-Endothelial Growth Factor Receptor 2; MiT: microphthalmia transcription factor tumors; PDAC: pancreatic ductal adenocarcinoma; NSCLC: non-small cell lung carcinoma; HCC: hepatocellular carcinoma; MTC: medullary thyroid carcinoma; GBM: glioblastoma; RCC: renal cell carcinoma; HNSCC: head and neck squamous cell cainoma; IND: Investigational New Drug.<sup id="cite_ref-Underiner2010_12-19" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup></div></div></div></div></div>
<p>As of 2010<sup class="plainlinks noexcerpt noprint asof-tag update" style="display:none;"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit">&#91;update&#93;</a></sup> over a dozen Met pathway inhibitors, with varying kinase selectivity profiles ranging from highly selective to multi-targeted,<sup id="cite_ref-Underiner2010_12-20" class="reference"><a href="#cite_note-Underiner2010-12">&#91;12&#93;</a></sup> have been studied in the clinic and good progress has been achieved <sup id="cite_ref-Liu2010_17-5" class="reference"><a href="#cite_note-Liu2010-17">&#91;17&#93;</a></sup> (See table 1). (e.g. <a href="https://en.wikipedia.org/wiki/XL184" class="mw-redirect" title="XL184">XL184</a>(Cabozantinib), <a href="https://en.wikipedia.org/wiki/XL880" class="mw-redirect" title="XL880">XL880</a>, <a href="https://en.wikipedia.org/wiki/ARQ197" class="mw-redirect" title="ARQ197">ARQ197</a> ) <sup class="noprint Inline-Template" style="margin-left:0.1em; white-space:nowrap;">&#91;<i><a href="https://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items" title="Wikipedia:Manual of Style/Dates and numbers"><span title="The text near this tag is dated. (December 2011)">needs update</span></a></i>&#93;</sup> 
</p><p>The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including <a href="https://en.wikipedia.org/wiki/Chemotherapy" title="Chemotherapy">chemo</a>-, <a href="https://en.wikipedia.org/wiki/Radiotherapy" class="mw-redirect" title="Radiotherapy">radio</a>- or <a href="https://en.wikipedia.org/wiki/Immunotherapy" title="Immunotherapy">immunotherapy</a> as well as different Met pathway inhibitor, f.ex. in with HGF and Met biological antagonists or antibodies against HGF and MET.<sup id="cite_ref-Liu2010_17-6" class="reference"><a href="#cite_note-Liu2010-17">&#91;17&#93;</a></sup>  Still, the risk of accumulated toxicity and interactions with other drugs remains.<sup id="cite_ref-Porter2010_10-20" class="reference"><a href="#cite_note-Porter2010-10">&#91;10&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Since_2010">Since 2010</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=16" title="Edit section: Since 2010">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In 2011 PF-02341066 (now named crizotinib) was approved by <a href="https://en.wikipedia.org/wiki/US_FDA" class="mw-redirect" title="US FDA">US FDA</a> for some <a href="https://en.wikipedia.org/wiki/Non-small_cell_lung_cancer" class="mw-redirect" title="Non-small cell lung cancer">non-small cell lung cancers</a>.
</p><p>In 2012 XL184/cabozantinib gained FDA approval to treat <a href="https://en.wikipedia.org/wiki/Medullary_thyroid_cancer" title="Medullary thyroid cancer">medullary thyroid cancer</a>, and in 2016 it gained FDA and EU approval to treat kidney cancer.
</p>
<table class="box-Expand_section plainlinks metadata ambox mbox-small-left ambox-content" role="presentation"><tbody><tr><td class="mbox-image"><a href="https://en.wikipedia.org/wiki/File:Wiki_letter_w_cropped.svg" class="image"><img alt="[icon]" src="http://upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png" decoding="async" width="20" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/30px-Wiki_letter_w_cropped.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/40px-Wiki_letter_w_cropped.svg.png 2x" data-file-width="44" data-file-height="31" /></a></td><td class="mbox-text"><div class="mbox-text-span">This section <b>needs expansion</b>. You can help by <a class="external text" href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=">adding to it</a>.  <span class="date-container"><i>(<span class="date">June 2018</span>)</i></span></div></td></tr></tbody></table>
<h3><span class="mw-headline" id="Research_on_other_inhibitors">Research on other inhibitors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=17" title="Edit section: Research on other inhibitors">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="https://en.wikipedia.org/wiki/Tepotinib" title="Tepotinib">Tepotinib</a>, (MSC 2156119J),<sup id="cite_ref-24" class="reference"><a href="#cite_note-24">&#91;24&#93;</a></sup></p><table class="box-Ref_expand plainlinks metadata ambox ambox-content ambox-Refimprove" role="presentation"><tbody><tr><td class="mbox-image"><div style="width:52px"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/a/a4/Text_document_with_red_question_mark.svg/40px-Text_document_with_red_question_mark.svg.png" decoding="async" width="40" height="40" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/a/a4/Text_document_with_red_question_mark.svg/60px-Text_document_with_red_question_mark.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a4/Text_document_with_red_question_mark.svg/80px-Text_document_with_red_question_mark.svg.png 2x" data-file-width="48" data-file-height="48" /></div></td><td class="mbox-text"><div class="mbox-text-span">This article <b>needs more complete <a href="https://en.wikipedia.org/wiki/Wikipedia:Citing_sources" title="Wikipedia:Citing sources">citations</a> for <a href="https://en.wikipedia.org/wiki/Wikipedia:Verifiability" title="Wikipedia:Verifiability">verification</a></b>.<span class="hide-when-compact"> Please help <a class="external text" href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit">improve this article</a> by <a href="https://en.wikipedia.org/wiki/Help:Introduction_to_referencing_with_Wiki_Markup/1" title="Help:Introduction to referencing with Wiki Markup/1">adding missing citation information</a> so that sources are clearly identifiable. Citations should include title, publication, author, date, and (for paginated material) the page number(s). <a href="https://en.wikipedia.org/wiki/Wikipedia:Template_messages/Sources_of_articles#Examples" class="mw-redirect" title="Wikipedia:Template messages/Sources of articles">Several templates</a>  are available to assist in formatting. Improperly sourced material may be challenged and removed.</span>  <span class="date-container"><i>(<span class="date">November 2020</span>)</i></span><span class="hide-when-compact"><i> (<small><a href="https://en.wikipedia.org/wiki/Help:Maintenance_template_removal" title="Help:Maintenance template removal">Learn how and when to remove this template message</a></small>)</i></span></div></td></tr></tbody></table><p> has reported phase II clinical trial results on lung cancer.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25">&#91;25&#93;</a></sup> Tepotinib was granted <a href="https://en.wikipedia.org/wiki/Breakthrough_therapy" title="Breakthrough therapy">breakthrough therapy</a> designation by the U.S. <a href="https://en.wikipedia.org/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) in September 2019.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup> It was granted <a href="https://en.wikipedia.org/wiki/Orphan_drug" title="Orphan drug">orphan drug</a> designation in Japan in November 2019, and in Australia in September 2020.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup>
</p><h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=18" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul><li><a href="https://en.wikipedia.org/wiki/Mesenchymal-epithelial_transition" class="mw-redirect" title="Mesenchymal-epithelial transition">Mesenchymal-epithelial transition</a></li>
<li><a href="https://en.wikipedia.org/wiki/Hepatocyte_growth_factor" title="Hepatocyte growth factor">Hepatocyte growth factor</a></li>
<li><a href="https://en.wikipedia.org/wiki/K252a" title="K252a">K252a</a></li>
<li><a href="https://en.wikipedia.org/wiki/Epithelial-mesenchymal_transition" class="mw-redirect" title="Epithelial-mesenchymal transition">Epithelial-mesenchymal transition</a></li>
<li><a href="https://en.wikipedia.org/wiki/C-Met" title="C-Met">c-Met</a></li></ul>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=19" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul><li><a rel="nofollow" class="external text" href="https://ccrod.cancer.gov/confluence/display/CCRHGF/Home">Experimental Cancer Therapeutics Targeting the Hepatocyte Growth Factor/Met Signaling Pathway</a></li></ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit&amp;section=20" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<style data-mw-deduplicate="TemplateStyles:r1011085734">.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}</style><div class="reflist">
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-pmid21740293-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid21740293_1-0">^</a></b></span> <span class="reference-text"><style data-mw-deduplicate="TemplateStyles:r1067248974">.mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("http://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("http://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("http://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("http://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style><cite id="CITEREFLiuNewtonScherle2011" class="citation journal cs1">Liu X, Newton RC, Scherle PA (September 2011). "Development of c-MET pathway inhibitors". <i>Expert Opin Investig Drugs</i>. <b>20</b> (9): 1225–41. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1517%2F13543784.2011.600687">10.1517/13543784.2011.600687</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/21740293">21740293</a>. <a href="https://en.wikipedia.org/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:24415851">24415851</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Opin+Investig+Drugs&amp;rft.atitle=Development+of+c-MET+pathway+inhibitors&amp;rft.volume=20&amp;rft.issue=9&amp;rft.pages=1225-41&amp;rft.date=2011-09&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A24415851%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F21740293&amp;rft_id=info%3Adoi%2F10.1517%2F13543784.2011.600687&amp;rft.aulast=Liu&amp;rft.aufirst=X&amp;rft.au=Newton%2C+RC&amp;rft.au=Scherle%2C+PA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKazandjian2014" class="citation journal cs1">Kazandjian, D;  et&#160;al. (Oct 2014). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201002">"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements"</a>. <i>Oncologist</i>. <b>19</b> (10): e5-11. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1634%2Ftheoncologist.2014-0241">10.1634/theoncologist.2014-0241</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201002">4201002</a></span>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/25170012">25170012</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Oncologist&amp;rft.atitle=FDA+approval+summary%3A+crizotinib+for+the+treatment+of+metastatic+non-small+cell+lung+cancer+with+anaplastic+lymphoma+kinase+rearrangements.&amp;rft.volume=19&amp;rft.issue=10&amp;rft.pages=e5-11&amp;rft.date=2014-10&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4201002%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F25170012&amp;rft_id=info%3Adoi%2F10.1634%2Ftheoncologist.2014-0241&amp;rft.aulast=Kazandjian&amp;rft.aufirst=D&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4201002&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-FDA2012-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-FDA2012_3-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm330143.htm">"FDA approves Cometriq to treat rare type of thyroid cancer"</a>. <i><a href="https://en.wikipedia.org/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a></i>. 29 November 2012.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Food+and+Drug+Administration&amp;rft.atitle=FDA+approves+Cometriq+to+treat+rare+type+of+thyroid+cancer&amp;rft.date=2012-11-29&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm330143.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Comoglio2008-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-Comoglio2008_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Comoglio2008_4-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFComoglioGiordanoTrusolino2008" class="citation journal cs1">Comoglio PM, Giordano S, Trusolino L (June 2008). "Drug development of MET inhibitors: targeting oncogene addiction and expedience". <i>Nature Reviews Drug Discovery</i>. <b>7</b> (6): 504–16. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fnrd2530">10.1038/nrd2530</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/18511928">18511928</a>. <a href="https://en.wikipedia.org/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:24601127">24601127</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews+Drug+Discovery&amp;rft.atitle=Drug+development+of+MET+inhibitors%3A+targeting+oncogene+addiction+and+expedience&amp;rft.volume=7&amp;rft.issue=6&amp;rft.pages=504-16&amp;rft.date=2008-06&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A24601127%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F18511928&amp;rft_id=info%3Adoi%2F10.1038%2Fnrd2530&amp;rft.aulast=Comoglio&amp;rft.aufirst=PM&amp;rft.au=Giordano%2C+S&amp;rft.au=Trusolino%2C+L&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Maulik2002-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-Maulik2002_5-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFMaulikShrikhandeKijimaMa2002" class="citation journal cs1">Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R (February 2002). "Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition". <i>Cytokine Growth Factor Rev</i>. <b>13</b> (1): 41–59. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2FS1359-6101(01)00029-6">10.1016/S1359-6101(01)00029-6</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/11750879">11750879</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cytokine+Growth+Factor+Rev.&amp;rft.atitle=Role+of+the+hepatocyte+growth+factor+receptor%2C+c-Met%2C+in+oncogenesis+and+potential+for+therapeutic+inhibition&amp;rft.volume=13&amp;rft.issue=1&amp;rft.pages=41-59&amp;rft.date=2002-02&amp;rft_id=info%3Adoi%2F10.1016%2FS1359-6101%2801%2900029-6&amp;rft_id=info%3Apmid%2F11750879&amp;rft.aulast=Maulik&amp;rft.aufirst=G&amp;rft.au=Shrikhande%2C+A&amp;rft.au=Kijima%2C+T&amp;rft.au=Ma%2C+PC&amp;rft.au=Morrison%2C+PT&amp;rft.au=Salgia%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Davis2010-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-Davis2010_6-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFDavisMcFaddenZhangCoxon2010" class="citation journal cs1">Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE (January 2010). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807989">"Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma"</a>. <i>Cancer Res</i>. <b>70</b> (2): 639–45. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1158%2F0008-5472.CAN-09-1121">10.1158/0008-5472.CAN-09-1121</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807989">2807989</a></span>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/20068147">20068147</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Res.&amp;rft.atitle=Identification+of+the+receptor+tyrosine+kinase+c-Met+and+its+ligand%2C+hepatocyte+growth+factor%2C+as+therapeutic+targets+in+clear+cell+sarcoma&amp;rft.volume=70&amp;rft.issue=2&amp;rft.pages=639-45&amp;rft.date=2010-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2807989%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F20068147&amp;rft_id=info%3Adoi%2F10.1158%2F0008-5472.CAN-09-1121&amp;rft.aulast=Davis&amp;rft.aufirst=IJ&amp;rft.au=McFadden%2C+AW&amp;rft.au=Zhang%2C+Y&amp;rft.au=Coxon%2C+A&amp;rft.au=Burgess%2C+TL&amp;rft.au=Wagner%2C+AJ&amp;rft.au=Fisher%2C+DE&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2807989&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Porter2009-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-Porter2009_7-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPorterLumbFranklinGascon-Simorte2009" class="citation journal cs1">Porter J, Lumb S, Franklin RJ, Gascon-Simorte JM, Calmiano M, Riche KL, Lallemand B, Keyaerts J, Edwards H, Maloney A, Delgado J, King L, Foley A, Lecomte F, Reuberson J, Meier C, Batchelor M (May 2009). "Discovery of 4-azaindoles as novel inhibitors of c-Met kinase". <i>Bioorg. Med. Chem. Lett</i>. <b>19</b> (10): 2780–4. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.bmcl.2009.03.110">10.1016/j.bmcl.2009.03.110</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/19369077">19369077</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bioorg.+Med.+Chem.+Lett.&amp;rft.atitle=Discovery+of+4-azaindoles+as+novel+inhibitors+of+c-Met+kinase&amp;rft.volume=19&amp;rft.issue=10&amp;rft.pages=2780-4&amp;rft.date=2009-05&amp;rft_id=info%3Adoi%2F10.1016%2Fj.bmcl.2009.03.110&amp;rft_id=info%3Apmid%2F19369077&amp;rft.aulast=Porter&amp;rft.aufirst=J&amp;rft.au=Lumb%2C+S&amp;rft.au=Franklin%2C+RJ&amp;rft.au=Gascon-Simorte%2C+JM&amp;rft.au=Calmiano%2C+M&amp;rft.au=Riche%2C+KL&amp;rft.au=Lallemand%2C+B&amp;rft.au=Keyaerts%2C+J&amp;rft.au=Edwards%2C+H&amp;rft.au=Maloney%2C+A&amp;rft.au=Delgado%2C+J&amp;rft.au=King%2C+L&amp;rft.au=Foley%2C+A&amp;rft.au=Lecomte%2C+F&amp;rft.au=Reuberson%2C+J&amp;rft.au=Meier%2C+C&amp;rft.au=Batchelor%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Schiering2003-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-Schiering2003_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Schiering2003_8-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSchieringKnappMarconiFlocco2003" class="citation cs2">Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C (October 2003), "Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a", <i>Proc. Natl. Acad. Sci. U.S.A.</i>, <b>100</b> (22): 12654–12659, <a href="https://en.wikipedia.org/wiki/Bibcode_(identifier)" class="mw-redirect" title="Bibcode (identifier)">Bibcode</a>:<a rel="nofollow" class="external text" href="https://ui.adsabs.harvard.edu/abs/2003PNAS..10012654S">2003PNAS..10012654S</a>, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1073%2Fpnas.1734128100">10.1073/pnas.1734128100</a></span>, <a href="https://en.wikipedia.org/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC240673">240673</a></span>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/14559966">14559966</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;rft.atitle=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+c-Met+and+its+complex+with+the+microbial+alkaloid+K-252a&amp;rft.volume=100&amp;rft.issue=22&amp;rft.pages=12654-12659&amp;rft.date=2003-10&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC240673%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F14559966&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.1734128100&amp;rft_id=info%3Abibcode%2F2003PNAS..10012654S&amp;rft.aulast=Schiering&amp;rft.aufirst=N&amp;rft.au=Knapp%2C+S&amp;rft.au=Marconi%2C+M&amp;rft.au=Flocco%2C+MM&amp;rft.au=Cui%2C+J&amp;rft.au=Perego%2C+R&amp;rft.au=Rusconi%2C+L&amp;rft.au=Cristiani%2C+C&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Sattler2003-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-Sattler2003_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Sattler2003_9-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSattlerPrideMaGramlich2003" class="citation cs2">Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang CX, Podar K, Christensen JG, Salgia R (September 2003), "A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase", <i>Cancer Research</i>, <b>63</b> (17): 5462–5469, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/14500382">14500382</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Research&amp;rft.atitle=A+novel+small+molecule+Met+inhibitor+induces+apoptosis+in+cells+transformed+by+the+oncogenic+TPR-MET+tyrosine+kinase&amp;rft.volume=63&amp;rft.issue=17&amp;rft.pages=5462-5469&amp;rft.date=2003-09&amp;rft_id=info%3Apmid%2F14500382&amp;rft.aulast=Sattler&amp;rft.aufirst=M&amp;rft.au=Pride%2C+YB&amp;rft.au=Ma%2C+P&amp;rft.au=Gramlich%2C+JL&amp;rft.au=Chu%2C+SC&amp;rft.au=Quinnan%2C+LA&amp;rft.au=Shirazian%2C+S&amp;rft.au=Liang%2C+CX&amp;rft.au=Podar%2C+K&amp;rft.au=Christensen%2C+JG&amp;rft.au=Salgia%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Porter2010-10"><span class="mw-cite-backlink">^ <a href="#cite_ref-Porter2010_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Porter2010_10-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Porter2010_10-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Porter2010_10-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Porter2010_10-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Porter2010_10-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Porter2010_10-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Porter2010_10-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Porter2010_10-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Porter2010_10-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Porter2010_10-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Porter2010_10-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Porter2010_10-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Porter2010_10-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Porter2010_10-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Porter2010_10-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Porter2010_10-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Porter2010_10-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Porter2010_10-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Porter2010_10-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Porter2010_10-20"><sup><i><b>u</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFPorter,_J2010" class="citation cs2">Porter, J (February 2010), "Small molecule c-Met kinase inhibitors: a review of recent patents", <i>Expert Opinion on Therapeutic Patents</i>, <b>20</b> (2): 159–177, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1517%2F13543770903514137">10.1517/13543770903514137</a>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/20100000">20100000</a>, <a href="https://en.wikipedia.org/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:22743228">22743228</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Opinion+on+Therapeutic+Patents&amp;rft.atitle=Small+molecule+c-Met+kinase+inhibitors%3A+a+review+of+recent+patents&amp;rft.volume=20&amp;rft.issue=2&amp;rft.pages=159-177&amp;rft.date=2010-02&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A22743228%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F20100000&amp;rft_id=info%3Adoi%2F10.1517%2F13543770903514137&amp;rft.au=Porter%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Christensen2003-11"><span class="mw-cite-backlink">^ <a href="#cite_ref-Christensen2003_11-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Christensen2003_11-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Christensen2003_11-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Christensen2003_11-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Christensen2003_11-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFChristensenSchreckBurrowsKuruganti2003" class="citation cs2">Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang XY, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JR, Cherrington JM, Mendel DB (November 2003), "A selective small molecule inhibitor of c-Met kinase inhibits c-Met dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo", <i>Cancer Research</i>, <b>63</b> (21): 7345–55, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/14612533">14612533</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Research&amp;rft.atitle=A+selective+small+molecule+inhibitor+of+c-Met+kinase+inhibits+c-Met+dependent+phenotypes+in+vitro+and+exhibits+cytoreductive+antitumor+activity+in+vivo&amp;rft.volume=63&amp;rft.issue=21&amp;rft.pages=7345-55&amp;rft.date=2003-11&amp;rft_id=info%3Apmid%2F14612533&amp;rft.aulast=Christensen&amp;rft.aufirst=JG&amp;rft.au=Schreck%2C+R&amp;rft.au=Burrows%2C+J&amp;rft.au=Kuruganti%2C+P&amp;rft.au=Chan%2C+E&amp;rft.au=Le%2C+P&amp;rft.au=Chen%2C+J&amp;rft.au=Wang%2C+XY&amp;rft.au=Ruslim%2C+L&amp;rft.au=Blake%2C+R&amp;rft.au=Lipson%2C+KE&amp;rft.au=Ramphal%2C+J&amp;rft.au=Do%2C+S&amp;rft.au=Cui%2C+JR&amp;rft.au=Cherrington%2C+JM&amp;rft.au=Mendel%2C+DB&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Underiner2010-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-Underiner2010_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Underiner2010_12-20"><sup><i><b>u</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFUnderinerHerbertzMiknyoczki2010" class="citation cs2">Underiner TL, Herbertz T, Miknyoczki SJ (January 2010), "Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates", <i>Anti-Cancer Agents in Medicinal Chemistry</i>, <b>10</b> (1): 7–27, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2174%2F1871520611009010007">10.2174/1871520611009010007</a>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/20015007">20015007</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Anti-Cancer+Agents+in+Medicinal+Chemistry&amp;rft.atitle=Discovery+of+Small+Molecule+c-Met+Inhibitors%3A+Evolution+and+Profiles+of+Clinical+Candidates&amp;rft.volume=10&amp;rft.issue=1&amp;rft.pages=7-27&amp;rft.date=2010-01&amp;rft_id=info%3Adoi%2F10.2174%2F1871520611009010007&amp;rft_id=info%3Apmid%2F20015007&amp;rft.aulast=Underiner&amp;rft.aufirst=TL&amp;rft.au=Herbertz%2C+T&amp;rft.au=Miknyoczki%2C+SJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Sattler2009-13"><span class="mw-cite-backlink">^ <a href="#cite_ref-Sattler2009_13-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Sattler2009_13-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Sattler2009_13-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Sattler2009_13-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFSattlerSalgia2009" class="citation cs2">Sattler M, Salgia R (April 2009), "The Met axis as a therapeutic target", <i>Update on Cancer Therapeutics</i>, <b>3</b> (3): 109–118, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.uct.2009.01.001">10.1016/j.uct.2009.01.001</a>, <a href="https://en.wikipedia.org/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847295">2847295</a></span>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/20368753">20368753</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Update+on+Cancer+Therapeutics&amp;rft.atitle=The+Met+axis+as+a+therapeutic+target&amp;rft.volume=3&amp;rft.issue=3&amp;rft.pages=109-118&amp;rft.date=2009-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2847295%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F20368753&amp;rft_id=info%3Adoi%2F10.1016%2Fj.uct.2009.01.001&amp;rft.aulast=Sattler&amp;rft.aufirst=M&amp;rft.au=Salgia%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Christensen2005-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-Christensen2005_14-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFChristensen_JGBurrows_JSalgia_R.2005" class="citation cs2">Christensen JG; Burrows J; Salgia R. (July 2005), "c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention", <i>Cancer Letters</i>, <b>225</b> (1): 1–26, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.canlet.2004.09.044">10.1016/j.canlet.2004.09.044</a>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/15922853">15922853</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Letters&amp;rft.atitle=c-Met+as+a+target+for+human+cancer+and+characterization+of+inhibitors+for+therapeutic+intervention&amp;rft.volume=225&amp;rft.issue=1&amp;rft.pages=1-26&amp;rft.date=2005-07&amp;rft_id=info%3Adoi%2F10.1016%2Fj.canlet.2004.09.044&amp;rft_id=info%3Apmid%2F15922853&amp;rft.au=Christensen+JG&amp;rft.au=Burrows+J&amp;rft.au=Salgia+R.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Knudsen2008-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-Knudsen2008_15-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKnudsenWoude2008" class="citation cs2">Knudsen BS, Woude GV (February 2008), "Showering c-MET-dependent cancers with drugs", <i>Current Opinion in Genetics &amp; Development</i>, <b>18</b> (1): 87–96, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.gde.2008.02.001">10.1016/j.gde.2008.02.001</a>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/18406132">18406132</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Opinion+in+Genetics+%26+Development&amp;rft.atitle=Showering+c-MET-dependent+cancers+with+drugs&amp;rft.volume=18&amp;rft.issue=1&amp;rft.pages=87-96&amp;rft.date=2008-02&amp;rft_id=info%3Adoi%2F10.1016%2Fj.gde.2008.02.001&amp;rft_id=info%3Apmid%2F18406132&amp;rft.aulast=Knudsen&amp;rft.aufirst=BS&amp;rft.au=Woude%2C+GV&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Bottaro2011-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-Bottaro2011_16-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFDonald_P._BottaroMegan_PeachMarec_NicklausTerrence_Burke,_JR.2011" class="citation cs2">Donald P. Bottaro; Megan Peach; Marec Nicklaus; Terrence Burke, JR.; Gagani Athauda; Sarah Choyke; Alessio Guibellino; Nelly Tan; Zhen-Dan Shi (August 2011), "Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling", <i>United States Patent Application Publication</i></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=United+States+Patent+Application+Publication&amp;rft.atitle=Compositions+and+methods+for+inhibition+of+hepatocyte+growth+factor+receptor+c-Met+signaling&amp;rft.date=2011-08&amp;rft.au=Donald+P.+Bottaro&amp;rft.au=Megan+Peach&amp;rft.au=Marec+Nicklaus&amp;rft.au=Terrence+Burke%2C+JR.&amp;rft.au=Gagani+Athauda&amp;rft.au=Sarah+Choyke&amp;rft.au=Alessio+Guibellino&amp;rft.au=Nelly+Tan&amp;rft.au=Zhen-Dan+Shi&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Liu2010-17"><span class="mw-cite-backlink">^ <a href="#cite_ref-Liu2010_17-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Liu2010_17-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Liu2010_17-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Liu2010_17-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Liu2010_17-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Liu2010_17-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Liu2010_17-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFLiuNewtonScherle2010" class="citation cs2">Liu XD, Newton RC, Scherle PA (January 2010), "Developing c-MET pathway inhibitors for cancer therapy: progress and challenges", <i>Trends in Molecular Medicine</i>, <b>16</b> (1): 37–45, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.molmed.2009.11.005">10.1016/j.molmed.2009.11.005</a>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/20031486">20031486</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Trends+in+Molecular+Medicine&amp;rft.atitle=Developing+c-MET+pathway+inhibitors+for+cancer+therapy%3A+progress+and+challenges&amp;rft.volume=16&amp;rft.issue=1&amp;rft.pages=37-45&amp;rft.date=2010-01&amp;rft_id=info%3Adoi%2F10.1016%2Fj.molmed.2009.11.005&amp;rft_id=info%3Apmid%2F20031486&amp;rft.aulast=Liu&amp;rft.aufirst=XD&amp;rft.au=Newton%2C+RC&amp;rft.au=Scherle%2C+PA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Kung2008-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-Kung2008_18-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKungFunkMengAlton2008" class="citation cs2">Kung PP, Funk L, Meng J, Alton G, Padrique E, Mroczkowski B (June 2008), "Structure activity relationships of quinoline-containing c-Met inhibitors", <i>European Journal of Medicinal Chemistry</i>, <b>43</b> (8): 1321–1329, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.ejmech.2007.08.011">10.1016/j.ejmech.2007.08.011</a>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/17964000">17964000</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Journal+of+Medicinal+Chemistry&amp;rft.atitle=Structure+activity+relationships+of+quinoline-containing+c-Met+inhibitors&amp;rft.volume=43&amp;rft.issue=8&amp;rft.pages=1321-1329&amp;rft.date=2008-06&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ejmech.2007.08.011&amp;rft_id=info%3Apmid%2F17964000&amp;rft.aulast=Kung&amp;rft.aufirst=PP&amp;rft.au=Funk%2C+L&amp;rft.au=Meng%2C+J&amp;rft.au=Alton%2C+G&amp;rft.au=Padrique%2C+E&amp;rft.au=Mroczkowski%2C+B&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Bellon2008-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-Bellon2008_19-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFBellon_SFKaplan-Lefko_PYang_YJZhang_YH2008" class="citation cs2">Bellon SF; Kaplan-Lefko P; Yang YJ; Zhang YH; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O‘Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I (February 2008), "c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations", <i>Journal of Biological Chemistry</i>, <b>283</b> (5): 2675–2683, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1074%2Fjbc.M705774200">10.1074/jbc.M705774200</a></span>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/18055465">18055465</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Biological+Chemistry&amp;rft.atitle=c-Met+inhibitors+with+novel+binding+mode+show+activity+against+several+hereditary+papillary+renal+cell+carcinoma-related+mutations&amp;rft.volume=283&amp;rft.issue=5&amp;rft.pages=2675-2683&amp;rft.date=2008-02&amp;rft_id=info%3Adoi%2F10.1074%2Fjbc.M705774200&amp;rft_id=info%3Apmid%2F18055465&amp;rft.au=Bellon+SF&amp;rft.au=Kaplan-Lefko+P&amp;rft.au=Yang+YJ&amp;rft.au=Zhang+YH&amp;rft.au=Moriguchi+J&amp;rft.au=Rex+K&amp;rft.au=Johnson+CW&amp;rft.au=Rose+PE&amp;rft.au=Long+AM&amp;rft.au=O%E2%80%98Connor+AB&amp;rft.au=Gu+Y&amp;rft.au=Coxon+A&amp;rft.au=Kim+TS&amp;rft.au=Tasker+A&amp;rft.au=Burgess+TL&amp;rft.au=Dussault+I&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Dussault2009-20"><span class="mw-cite-backlink">^ <a href="#cite_ref-Dussault2009_20-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Dussault2009_20-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Dussault2009_20-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFDussaultBellon2009" class="citation cs2">Dussault I, Bellon SF (February 2009), "From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer", <i>Anti-Cancer Agents in Medicinal Chemistry</i>, <b>9</b> (2): 221–229, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2174%2F187152009787313792">10.2174/187152009787313792</a>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/19199866">19199866</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Anti-Cancer+Agents+in+Medicinal+Chemistry&amp;rft.atitle=From+concept+to+reality%3A+the+long+road+to+c-Met+and+RON+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+cancer&amp;rft.volume=9&amp;rft.issue=2&amp;rft.pages=221-229&amp;rft.date=2009-02&amp;rft_id=info%3Adoi%2F10.2174%2F187152009787313792&amp;rft_id=info%3Apmid%2F19199866&amp;rft.aulast=Dussault&amp;rft.aufirst=I&amp;rft.au=Bellon%2C+SF&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Eathiraj2011-21"><span class="mw-cite-backlink">^ <a href="#cite_ref-Eathiraj2011_21-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Eathiraj2011_21-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Eathiraj2011_21-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Eathiraj2011_21-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Eathiraj2011_21-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Eathiraj2011_21-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFEathirajPalmaVolckovaHirschi2011" class="citation cs2">Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC (June 2011), "Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197", <i>Journal of Biological Chemistry</i>, <b>286</b> (23): 20666–20676, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1074%2Fjbc.M110.213801">10.1074/jbc.M110.213801</a></span>, <a href="https://en.wikipedia.org/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121448">3121448</a></span>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/21454604">21454604</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Biological+Chemistry&amp;rft.atitle=Discovery+of+a+Novel+Mode+of+Protein+Kinase+Inhibition+Characterized+by+the+Mechanism+of+Inhibition+of+Human+Mesenchymal-epithelial+Transition+Factor+%28c-Met%29+Protein+Autophosphorylation+by+ARQ+197&amp;rft.volume=286&amp;rft.issue=23&amp;rft.pages=20666-20676&amp;rft.date=2011-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3121448%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F21454604&amp;rft_id=info%3Adoi%2F10.1074%2Fjbc.M110.213801&amp;rft.aulast=Eathiraj&amp;rft.aufirst=S&amp;rft.au=Palma%2C+R&amp;rft.au=Volckova%2C+E&amp;rft.au=Hirschi%2C+M&amp;rft.au=France%2C+DS&amp;rft.au=Ashwell%2C+MA&amp;rft.au=Chan%2C+TC&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Allen2011-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-Allen2011_22-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFAllenBardelleBladesButtar2011" class="citation cs2">Allen JV, Bardelle C, Blades K, Buttar D, Chapman L, Colclough N, Dossetter AG, Garner AP, Girdwood A, Lambert C, Leash AG, Law B, Major J, Plant H, Slater AM (September 2011), "The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach", <i>Bioorganic &amp; Medicinal Chemistry Letters</i>, <b>21</b> (18): 5224–5229, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.bmcl.2011.07.047">10.1016/j.bmcl.2011.07.047</a>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/21835616">21835616</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bioorganic+%26+Medicinal+Chemistry+Letters&amp;rft.atitle=The+discovery+of+benzanilides+as+c-Met+receptor+tyrosine+kinase+inhibitors+by+a+directed+screening+approach&amp;rft.volume=21&amp;rft.issue=18&amp;rft.pages=5224-5229&amp;rft.date=2011-09&amp;rft_id=info%3Adoi%2F10.1016%2Fj.bmcl.2011.07.047&amp;rft_id=info%3Apmid%2F21835616&amp;rft.aulast=Allen&amp;rft.aufirst=JV&amp;rft.au=Bardelle%2C+C&amp;rft.au=Blades%2C+K&amp;rft.au=Buttar%2C+D&amp;rft.au=Chapman%2C+L&amp;rft.au=Colclough%2C+N&amp;rft.au=Dossetter%2C+AG&amp;rft.au=Garner%2C+AP&amp;rft.au=Girdwood%2C+A&amp;rft.au=Lambert%2C+C&amp;rft.au=Leash%2C+AG&amp;rft.au=Law%2C+B&amp;rft.au=Major%2C+J&amp;rft.au=Plant%2C+H&amp;rft.au=Slater%2C+AM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-Katz2011-23"><span class="mw-cite-backlink">^ <a href="#cite_ref-Katz2011_23-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Katz2011_23-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Katz2011_23-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite id="CITEREFKatzJewellGuerinLim2011" class="citation cs2">Katz JD, Jewell JP, Guerin DJ, Lim J, Dinsmore CJ, Deshmukh SV, Pan BS, Marshall CG, Lu W, Altman MD, Dahlberg WK, Davis L, Falcone D, Gabarda AE, Hang GZ, Hatch H, Holmes R, Kunii K, Lumb KJ, Lutterbach B, Mathvink R, Nazef N, Patel SB, Qu XL, Reilly JF, Rickert KW, Rosenstein C, Soisson SM, Spencer KB, Szewczak AA, Walker D, Wang WX, Young J, Zeng QW (June 2011), "Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer", <i>Journal of Medicinal Chemistry</i>, <b>54</b> (12): 4092–4108, <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1021%2Fjm200112k">10.1021/jm200112k</a>, <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="http://pubmed.ncbi.nlm.nih.gov/21608528">21608528</a></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Medicinal+Chemistry&amp;rft.atitle=Discovery+of+a+5H-Benzo%5B4%2C5%5Dcyclohepta%5B1%2C2-b%5Dpyridin-5-one+%28MK-2461%29+Inhibitor+of+c-Met+Kinase+for+the+Treatment+of+Cancer&amp;rft.volume=54&amp;rft.issue=12&amp;rft.pages=4092-4108&amp;rft.date=2011-06&amp;rft_id=info%3Adoi%2F10.1021%2Fjm200112k&amp;rft_id=info%3Apmid%2F21608528&amp;rft.aulast=Katz&amp;rft.aufirst=JD&amp;rft.au=Jewell%2C+JP&amp;rft.au=Guerin%2C+DJ&amp;rft.au=Lim%2C+J&amp;rft.au=Dinsmore%2C+CJ&amp;rft.au=Deshmukh%2C+SV&amp;rft.au=Pan%2C+BS&amp;rft.au=Marshall%2C+CG&amp;rft.au=Lu%2C+W&amp;rft.au=Altman%2C+MD&amp;rft.au=Dahlberg%2C+WK&amp;rft.au=Davis%2C+L&amp;rft.au=Falcone%2C+D&amp;rft.au=Gabarda%2C+AE&amp;rft.au=Hang%2C+GZ&amp;rft.au=Hatch%2C+H&amp;rft.au=Holmes%2C+R&amp;rft.au=Kunii%2C+K&amp;rft.au=Lumb%2C+KJ&amp;rft.au=Lutterbach%2C+B&amp;rft.au=Mathvink%2C+R&amp;rft.au=Nazef%2C+N&amp;rft.au=Patel%2C+SB&amp;rft.au=Qu%2C+XL&amp;rft.au=Reilly%2C+JF&amp;rft.au=Rickert%2C+KW&amp;rft.au=Rosenstein%2C+C&amp;rft.au=Soisson%2C+SM&amp;rft.au=Spencer%2C+KB&amp;rft.au=Szewczak%2C+AA&amp;rft.au=Walker%2C+D&amp;rft.au=Wang%2C+WX&amp;rft.au=Young%2C+J&amp;rft.au=Zeng%2C+QW&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://clinicaltrials.gov/ct2/show/NCT01982955"><i>Tepotinib With Gefitinib in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (INSIGHT)</i></a></span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e20541"><i>Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations.</i> 2017</a></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.emdgroup.com/en/news/tepotinib-breakthrough-therapy-designation-11-09-2019.html">"Tepotinib Breakthrough Therapy"</a>. <i>Merck KGaA, Darmstadt, Germany</i> (Press release). 11 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">8 November</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Tepotinib+Breakthrough+Therapy&amp;rft.date=2019-09-11&amp;rft_id=https%3A%2F%2Fwww.emdgroup.com%2Fen%2Fnews%2Ftepotinib-breakthrough-therapy-designation-11-09-2019.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1067248974"/><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.emdgroup.com/en/news/orphan-drug-designation-20-11-2019.html">"Orphan Drug Designation"</a>. <i>Merck KGaA, Darmstadt, Germany</i> (Press release). 20 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">8 November</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Orphan+Drug+Designation&amp;rft.date=2019-11-20&amp;rft_id=https%3A%2F%2Fwww.emdgroup.com%2Fen%2Fnews%2Forphan-drug-designation-20-11-2019.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AC-Met+inhibitor" class="Z3988"></span></span>
</li>
</ol></div></div>
<div class="navbox-styles nomobile"><style data-mw-deduplicate="TemplateStyles:r1061467846">.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}</style></div><div role="navigation" class="navbox" aria-labelledby="Drug_design" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><style data-mw-deduplicate="TemplateStyles:r1063604349">.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}</style><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="https://en.wikipedia.org/wiki/Template:Drug_design" title="Template:Drug design"><abbr title="View this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">v</abbr></a></li><li class="nv-talk"><a href="https://en.wikipedia.org/wiki/Template_talk:Drug_design" title="Template talk:Drug design"><abbr title="Discuss this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=Template:Drug_design&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">e</abbr></a></li></ul></div><div id="Drug_design" style="font-size:114%;margin:0 4em"><a href="https://en.wikipedia.org/wiki/Drug_design" title="Drug design">Drug design</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Steps in design</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="https://en.wikipedia.org/wiki/Drug_discovery" title="Drug discovery">Drug discovery</a></li>
<li><a href="https://en.wikipedia.org/wiki/Hit_to_lead" title="Hit to lead">Hit to lead</a></li>
<li><a href="https://en.wikipedia.org/wiki/Drug_development" title="Drug development">Drug development</a>
<ul><li><a href="https://en.wikipedia.org/wiki/Preclinical_development" title="Preclinical development">Preclinical</a></li>
<li><a href="https://en.wikipedia.org/wiki/Clinical_trial" title="Clinical trial">Clinical</a>
<ul><li><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research" title="Phases of clinical research">Phases</a></li></ul></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Case studies of discovery <br /> and development of drug classes</th><td class="navbox-list-with-group navbox-list navbox-even hlist" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_5α-reductase_inhibitors" title="Discovery and development of 5α-reductase inhibitors">5α-Reductase inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_ACE_inhibitors" title="Discovery and development of ACE inhibitors">ACE inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_angiotensin_receptor_blockers" title="Discovery and development of angiotensin receptor blockers">Angiotensin receptor blockers</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_antiandrogens" title="Discovery and development of antiandrogens">Antiandrogens</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_beta-adrenergic_receptor_antagonists_(beta-blockers)" class="mw-redirect" title="Discovery and development of beta-adrenergic receptor antagonists (beta-blockers)">Beta-blockers</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_beta2_agonists" title="Discovery and development of beta2 agonists">Beta<sub>2</sub> agonists</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_cephalosporins" title="Discovery and development of cephalosporins">Cephalosporins</a></li>
<li><a href="https://en.wikipedia.org/wiki/C-Met_inhibitors" class="mw-redirect" title="C-Met inhibitors">c-Met inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_cyclooxygenase_2_inhibitors" title="Discovery and development of cyclooxygenase 2 inhibitors">Cyclooxygenase 2 inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Development_of_dipeptidyl_peptidase-4_inhibitors" class="mw-redirect" title="Development of dipeptidyl peptidase-4 inhibitors">Dipeptidyl peptidase-4 inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_direct_thrombin_inhibitors" title="Discovery and development of direct thrombin inhibitors">Direct thrombin inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_direct_Xa_inhibitors" title="Discovery and development of direct Xa inhibitors">Direct Xa inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_dual_serotonin_and_norepinephrine_reuptake_inhibitors" class="mw-redirect" title="Discovery and development of dual serotonin and norepinephrine reuptake inhibitors">Dual serotonin and norepinephrine reuptake inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Development_and_discovery_of_SSRI_drugs" title="Development and discovery of SSRI drugs">Selective serotonin reuptake inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_gliflozins" title="Discovery and development of gliflozins">Gliflozins</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_HIV-protease_inhibitors" title="Discovery and development of HIV-protease inhibitors">HIV-protease inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_integrase_inhibitors" title="Discovery and development of integrase inhibitors">Integrase inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_gastrointestinal_lipase_inhibitors" title="Discovery and development of gastrointestinal lipase inhibitors">Lipase inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_memantine_and_related_compounds" class="mw-redirect" title="Discovery and development of memantine and related compounds">Memantine and related drugs</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_mTOR_inhibitors" class="mw-redirect" title="Discovery and development of mTOR inhibitors">mTOR inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_Neuraminidase_Inhibitors" class="mw-redirect" title="Discovery and development of Neuraminidase Inhibitors">Neuraminidase inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_non-nucleoside_reverse-transcriptase_inhibitors" title="Discovery and development of non-nucleoside reverse-transcriptase inhibitors">Non-nucleoside reverse-transcriptase inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_NS5A_inhibitors" title="Discovery and development of NS5A inhibitors">NS5A inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_nucleoside_and_nucleotide_reverse-transcriptase_inhibitors" title="Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors">Nucleoside and nucleotide reverse-transcriptase inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_phosphodiesterase_5_inhibitors" title="Discovery and development of phosphodiesterase 5 inhibitors">PDE5 inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_proton_pump_inhibitors" title="Discovery and development of proton pump inhibitors">Proton pump inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_statins" title="Discovery and development of statins">Statins</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_thalidomide_and_its_analogs" class="mw-redirect" title="Discovery and development of thalidomide and its analogs">Thalidomide and its analogs</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_triptans" title="Discovery and development of triptans">Triptans</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_TRPV1_antagonists" title="Discovery and development of TRPV1 antagonists">TRPV1 antagonists</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_tubulin_inhibitors" title="Discovery and development of tubulin inhibitors">Tubulin inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_Bcr-Abl_tyrosine_kinase_inhibitors" class="mw-redirect" title="Discovery and development of Bcr-Abl tyrosine kinase inhibitors">Bcr-Abl tyrosine-kinase inhibitors</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_Cannabinoid_Receptor_1_Antagonists" class="mw-redirect" title="Discovery and development of Cannabinoid Receptor 1 Antagonists">Cannabinoid receptor antagonists</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_CCR5_receptor_antagonists" class="mw-redirect" title="Discovery and development of CCR5 receptor antagonists">CCR5 receptor antagonists</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_neurokinin_1_receptor_antagonists" class="mw-redirect" title="Discovery and development of neurokinin 1 receptor antagonists">Neurokinin 1 receptor antagonists</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_serotonin_receptor_antagonists" class="mw-redirect" title="Discovery and development of serotonin receptor antagonists">5-HT<sub>3</sub> antagonists</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_melatonin_receptor_agonists" class="mw-redirect" title="Discovery and development of melatonin receptor agonists">Melatonin receptor agonists</a></li>
<li><a href="https://en.wikipedia.org/wiki/Discovery_and_development_of_renin_inhibitors" class="mw-redirect" title="Discovery and development of renin inhibitors">Renin inhibitors</a></li></ul>
</div></td></tr></tbody></table></div>
<div class="navbox-styles nomobile"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1061467846"/></div><div role="navigation" class="navbox" aria-labelledby="Growth_factor_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="https://en.wikipedia.org/wiki/mw-data:TemplateStyles:r1063604349"/><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="https://en.wikipedia.org/wiki/Template:Growth_factor_receptor_modulators" title="Template:Growth factor receptor modulators"><abbr title="View this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">v</abbr></a></li><li class="nv-talk"><a href="https://en.wikipedia.org/wiki/Template_talk:Growth_factor_receptor_modulators" title="Template talk:Growth factor receptor modulators"><abbr title="Discuss this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=Template:Growth_factor_receptor_modulators&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;box-shadow:none;padding:0;">e</abbr></a></li></ul></div><div id="Growth_factor_receptor_modulators" style="font-size:114%;margin:0 4em"><a href="https://en.wikipedia.org/wiki/Growth_factor_receptor" title="Growth factor receptor">Growth factor receptor</a> <a href="https://en.wikipedia.org/wiki/Receptor_modulator" title="Receptor modulator">modulators</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Angiopoietin_receptor" title="Angiopoietin receptor">Angiopoietin</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Angiopoietin_1" title="Angiopoietin 1">Angiopoietin 1</a></li>
<li><a href="https://en.wikipedia.org/wiki/Angiopoietin_4" class="mw-redirect" title="Angiopoietin 4">Angiopoietin 4</a></li></ul>
<ul><li><i>Antagonists:</i> <a href="https://en.wikipedia.org/wiki/Angiopoietin_2" class="mw-redirect" title="Angiopoietin 2">Angiopoietin 2</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Angiopoietin_3&amp;action=edit&amp;redlink=1" class="new" title="Angiopoietin 3 (page does not exist)">Angiopoietin 3</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=Altiratinib&amp;action=edit&amp;redlink=1" class="new" title="Altiratinib (page does not exist)">Altiratinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=CE-245677&amp;action=edit&amp;redlink=1" class="new" title="CE-245677 (page does not exist)">CE-245677</a></li>
<li><a href="https://en.wikipedia.org/wiki/Rebastinib" class="mw-redirect" title="Rebastinib">Rebastinib</a></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/wiki/Evinacumab" title="Evinacumab">Evinacumab</a> (against angiopoietin 3)</li>
<li><a href="https://en.wikipedia.org/wiki/Nesvacumab" title="Nesvacumab">Nesvacumab</a> (against angiopoietin 2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Ciliary_neurotrophic_factor_receptor" title="Ciliary neurotrophic factor receptor">CNTF</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Axokine" class="mw-redirect" title="Axokine">Axokine</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ciliary_neurotrophic_factor_receptor" title="Ciliary neurotrophic factor receptor">CNTF</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Dapiclermin&amp;action=edit&amp;redlink=1" class="new" title="Dapiclermin (page does not exist)">Dapiclermin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor" title="Epidermal growth factor receptor">EGF (ErbB)</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor" title="Epidermal growth factor receptor">EGF<br /><small>(ErbB1/HER1)</small></a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists</i>: <a href="https://en.wikipedia.org/wiki/Amphiregulin" title="Amphiregulin">Amphiregulin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Betacellulin" title="Betacellulin">Betacellulin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Epidermal_growth_factor" title="Epidermal growth factor">EGF (urogastrone)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Epigen" title="Epigen">Epigen</a></li>
<li><a href="https://en.wikipedia.org/wiki/Epiregulin" title="Epiregulin">Epiregulin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Heparin-binding_EGF-like_growth_factor" title="Heparin-binding EGF-like growth factor">Heparin-binding EGF-like growth factor (HB-EGF)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Murodermin" title="Murodermin">Murodermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Nepidermin" title="Nepidermin">Nepidermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Transforming_growth_factor_alpha" class="mw-redirect" title="Transforming growth factor alpha">Transforming growth factor alpha (TGFα)</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/wiki/Afatinib" title="Afatinib">Afatinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Agerafenib&amp;action=edit&amp;redlink=1" class="new" title="Agerafenib (page does not exist)">Agerafenib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Brigatinib" title="Brigatinib">Brigatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Canertinib" title="Canertinib">Canertinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dacomitinib" title="Dacomitinib">Dacomitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Grandinin" title="Grandinin">Grandinin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Icotinib" title="Icotinib">Icotinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Neratinib" title="Neratinib">Neratinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Osimertinib" title="Osimertinib">Osimertinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=WHI-P_154&amp;action=edit&amp;redlink=1" class="new" title="WHI-P 154 (page does not exist)">WHI-P 154</a></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/wiki/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Depatuxizumab&amp;action=edit&amp;redlink=1" class="new" title="Depatuxizumab (page does not exist)">Depatuxizumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Depatuxizumab_mafodotin" title="Depatuxizumab mafodotin">Depatuxizumab mafodotin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Futuximab" title="Futuximab">Futuximab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Imgatuzumab" title="Imgatuzumab">Imgatuzumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Matuzumab" title="Matuzumab">Matuzumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Necitumumab" title="Necitumumab">Necitumumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Nimotuzumab" title="Nimotuzumab">Nimotuzumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Panitumumab" title="Panitumumab">Panitumumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Zalutumumab" title="Zalutumumab">Zalutumumab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/HER2/neu" title="HER2/neu">ErbB2/HER2</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists</i>: <i>Unknown/none</i></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/wiki/Ertumaxomab" title="Ertumaxomab">Ertumaxomab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Pertuzumab" title="Pertuzumab">Pertuzumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Trastuzumab" title="Trastuzumab">Trastuzumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan" title="Trastuzumab deruxtecan">Trastuzumab deruxtecan</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Trastuzumab_duocarmazine&amp;action=edit&amp;redlink=1" class="new" title="Trastuzumab duocarmazine (page does not exist)">Trastuzumab duocarmazine</a></li>
<li><a href="https://en.wikipedia.org/wiki/Trastuzumab_emtansine" title="Trastuzumab emtansine">Trastuzumab emtansine</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/wiki/Afatinib" title="Afatinib">Afatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Mubritinib" title="Mubritinib">Mubritinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Neratinib" title="Neratinib">Neratinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Tucatinib" title="Tucatinib">Tucatinib</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/HER3" class="mw-redirect" title="HER3">ErbB3/HER3</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Neuregulin" title="Neuregulin">Neuregulins (heregulins)</a> (<a href="https://en.wikipedia.org/wiki/Neuregulin-1" class="mw-redirect" title="Neuregulin-1">1</a>, <a href="https://en.wikipedia.org/wiki/NRG2" class="mw-redirect" title="NRG2">2</a>, <a href="https://en.wikipedia.org/wiki/CSPG5" title="CSPG5">6 (neuroglycan C)</a>)</li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/wiki/Duligotumab" class="mw-redirect" title="Duligotumab">Duligotumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Patritumab" title="Patritumab">Patritumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Seribantumab" title="Seribantumab">Seribantumab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/HER4" class="mw-redirect" title="HER4">ErbB4/HER4</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Betacellulin" title="Betacellulin">Betacellulin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Epigen" title="Epigen">Epigen</a></li>
<li><a href="https://en.wikipedia.org/wiki/Heparin-binding_EGF-like_growth_factor" title="Heparin-binding EGF-like growth factor">Heparin-binding EGF-like growth factor (HB-EGF)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Neuregulin" title="Neuregulin">Neuregulins (heregulins)</a> (<a href="https://en.wikipedia.org/wiki/Neuregulin-1" class="mw-redirect" title="Neuregulin-1">1</a>, <a href="https://en.wikipedia.org/wiki/NRG2" class="mw-redirect" title="NRG2">2</a>, <a href="https://en.wikipedia.org/wiki/NRG3" class="mw-redirect" title="NRG3">3</a>, <a href="https://en.wikipedia.org/wiki/NRG4" class="mw-redirect" title="NRG4">4</a>, <a href="https://en.wikipedia.org/w/index.php?title=Tomoregulin&amp;action=edit&amp;redlink=1" class="new" title="Tomoregulin (page does not exist)">5 (tomoregulin, TMEFF)</a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor" title="Fibroblast growth factor receptor">FGF</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_1" title="Fibroblast growth factor receptor 1">FGFR1</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/w/index.php?title=Ersofermin&amp;action=edit&amp;redlink=1" class="new" title="Ersofermin (page does not exist)">Ersofermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Fibroblast_growth_factor" title="Fibroblast growth factor">FGF</a> (<a href="https://en.wikipedia.org/wiki/FGF1" title="FGF1">1</a>, <a href="https://en.wikipedia.org/wiki/FGF2" class="mw-redirect" title="FGF2">2 (bFGF)</a>, <a href="https://en.wikipedia.org/wiki/FGF3" title="FGF3">3</a>, <a href="https://en.wikipedia.org/wiki/FGF4" title="FGF4">4</a>, <a href="https://en.wikipedia.org/wiki/FGF5" title="FGF5">5</a>, <a href="https://en.wikipedia.org/wiki/FGF6" title="FGF6">6</a>, <a href="https://en.wikipedia.org/wiki/FGF8" title="FGF8">8</a>, <a href="https://en.wikipedia.org/wiki/FGF10" title="FGF10">10 (KGF2)</a>, <a href="https://en.wikipedia.org/wiki/FGF20" title="FGF20">20</a>)</li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Repifermin&amp;action=edit&amp;redlink=1" class="new" title="Repifermin (page does not exist)">Repifermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Selpercatinib" title="Selpercatinib">Selpercatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Trafermin" title="Trafermin">Trafermin</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Velafermin&amp;action=edit&amp;redlink=1" class="new" title="Velafermin (page does not exist)">Velafermin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_2" title="Fibroblast growth factor receptor 2">FGFR2</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/w/index.php?title=Ersofermin&amp;action=edit&amp;redlink=1" class="new" title="Ersofermin (page does not exist)">Ersofermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Fibroblast_growth_factor" title="Fibroblast growth factor">FGF</a> (<a href="https://en.wikipedia.org/wiki/FGF1" title="FGF1">1</a>, <a href="https://en.wikipedia.org/wiki/FGF2" class="mw-redirect" title="FGF2">2 (bFGF)</a>, <a href="https://en.wikipedia.org/wiki/FGF3" title="FGF3">3</a>, <a href="https://en.wikipedia.org/wiki/FGF4" title="FGF4">4</a>, <a href="https://en.wikipedia.org/wiki/FGF5" title="FGF5">5</a>, <a href="https://en.wikipedia.org/wiki/FGF6" title="FGF6">6</a>, <a href="https://en.wikipedia.org/wiki/FGF7" title="FGF7">7</a> (<a href="https://en.wikipedia.org/wiki/Keratinocyte_growth_factor" title="Keratinocyte growth factor">KGF</a>), <a href="https://en.wikipedia.org/wiki/FGF8" title="FGF8">8</a>, <a href="https://en.wikipedia.org/wiki/FGF9" title="FGF9">9</a>, <a href="https://en.wikipedia.org/wiki/FGF10" title="FGF10">10 (KGF2)</a>, <a href="https://en.wikipedia.org/wiki/FGF17" title="FGF17">17</a>, <a href="https://en.wikipedia.org/wiki/FGF18" title="FGF18">18</a>, <a href="https://en.wikipedia.org/wiki/FGF22" title="FGF22">22</a>)</li>
<li><a href="https://en.wikipedia.org/wiki/Palifermin" title="Palifermin">Palifermin</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Repifermin&amp;action=edit&amp;redlink=1" class="new" title="Repifermin (page does not exist)">Repifermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Selpercatinib" title="Selpercatinib">Selpercatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Sprifermin" title="Sprifermin">Sprifermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Trafermin" title="Trafermin">Trafermin</a></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/w/index.php?title=Aprutumab&amp;action=edit&amp;redlink=1" class="new" title="Aprutumab (page does not exist)">Aprutumab</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Aprutumab_ixadotin&amp;action=edit&amp;redlink=1" class="new" title="Aprutumab ixadotin (page does not exist)">Aprutumab ixadotin</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/wiki/Infigratinib" title="Infigratinib">Infigratinib</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_3" title="Fibroblast growth factor receptor 3">FGFR3</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/w/index.php?title=Ersofermin&amp;action=edit&amp;redlink=1" class="new" title="Ersofermin (page does not exist)">Ersofermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Fibroblast_growth_factor" title="Fibroblast growth factor">FGF</a> (<a href="https://en.wikipedia.org/wiki/FGF1" title="FGF1">1</a>, <a href="https://en.wikipedia.org/wiki/FGF2" class="mw-redirect" title="FGF2">2 (bFGF)</a>, <a href="https://en.wikipedia.org/wiki/FGF4" title="FGF4">4</a>, <a href="https://en.wikipedia.org/wiki/FGF8" title="FGF8">8</a>, <a href="https://en.wikipedia.org/wiki/FGF9" title="FGF9">9</a>, <a href="https://en.wikipedia.org/wiki/FGF18" title="FGF18">18</a>, <a href="https://en.wikipedia.org/wiki/FGF23" class="mw-redirect" title="FGF23">23</a>)</li>
<li><a href="https://en.wikipedia.org/wiki/Selpercatinib" title="Selpercatinib">Selpercatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Sprifermin" title="Sprifermin">Sprifermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Trafermin" title="Trafermin">Trafermin</a></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/wiki/Burosumab" title="Burosumab">Burosumab</a> (against FGF23)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_4" title="Fibroblast growth factor receptor 4">FGFR4</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/w/index.php?title=Ersofermin&amp;action=edit&amp;redlink=1" class="new" title="Ersofermin (page does not exist)">Ersofermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Fibroblast_growth_factor" title="Fibroblast growth factor">FGF</a> (<a href="https://en.wikipedia.org/wiki/FGF1" title="FGF1">1</a>, <a href="https://en.wikipedia.org/wiki/FGF2" class="mw-redirect" title="FGF2">2 (bFGF)</a>, <a href="https://en.wikipedia.org/wiki/FGF4" title="FGF4">4</a>, <a href="https://en.wikipedia.org/wiki/FGF6" title="FGF6">6</a>, <a href="https://en.wikipedia.org/wiki/FGF8" title="FGF8">8</a>, <a href="https://en.wikipedia.org/wiki/FGF9" title="FGF9">9</a>, <a href="https://en.wikipedia.org/wiki/FGF19" title="FGF19">19</a>)</li>
<li><a href="https://en.wikipedia.org/wiki/Trafermin" title="Trafermin">Trafermin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/FGF15/19" title="FGF15/19">FGF15/19</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Hepatocyte_growth_factor_receptor" class="mw-redirect" title="Hepatocyte growth factor receptor">HGF (c-Met)</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists</i>: <a href="https://en.wikipedia.org/w/index.php?title=Fosgonimeton&amp;action=edit&amp;redlink=1" class="new" title="Fosgonimeton (page does not exist)">Fosgonimeton</a></li>
<li><a href="https://en.wikipedia.org/wiki/Hepatocyte_growth_factor" title="Hepatocyte growth factor">Hepatocyte growth factor</a></li></ul>
<ul><li><i>Potentiators:</i> <a href="https://en.wikipedia.org/wiki/Dihexa" title="Dihexa">Dihexa (PNB-0408)</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=Altiratinib&amp;action=edit&amp;redlink=1" class="new" title="Altiratinib (page does not exist)">Altiratinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=AM7_(drug)&amp;action=edit&amp;redlink=1" class="new" title="AM7 (drug) (page does not exist)">AM7</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=AMG-458&amp;action=edit&amp;redlink=1" class="new" title="AMG-458 (page does not exist)">AMG-458</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Amuvatinib&amp;action=edit&amp;redlink=1" class="new" title="Amuvatinib (page does not exist)">Amuvatinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=BMS-777607&amp;action=edit&amp;redlink=1" class="new" title="BMS-777607 (page does not exist)">BMS-777607</a></li>
<li><a href="https://en.wikipedia.org/wiki/Cabozantinib" title="Cabozantinib">Cabozantinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Capmatinib" title="Capmatinib">Capmatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Crizotinib" title="Crizotinib">Crizotinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Foretinib" title="Foretinib">Foretinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Golvatinib&amp;action=edit&amp;redlink=1" class="new" title="Golvatinib (page does not exist)">Golvatinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=INCB28060&amp;action=edit&amp;redlink=1" class="new" title="INCB28060 (page does not exist)">INCB28060</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=JNJ-38877605&amp;action=edit&amp;redlink=1" class="new" title="JNJ-38877605 (page does not exist)">JNJ-38877605</a></li>
<li><a href="https://en.wikipedia.org/wiki/K252a" title="K252a">K252a</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=MK-2461&amp;action=edit&amp;redlink=1" class="new" title="MK-2461 (page does not exist)">MK-2461</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=PF-04217903&amp;action=edit&amp;redlink=1" class="new" title="PF-04217903 (page does not exist)">PF-04217903</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=PF-2341066&amp;action=edit&amp;redlink=1" class="new" title="PF-2341066 (page does not exist)">PF-2341066</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=PHA-665752&amp;action=edit&amp;redlink=1" class="new" title="PHA-665752 (page does not exist)">PHA-665752</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=SU-11274&amp;action=edit&amp;redlink=1" class="new" title="SU-11274 (page does not exist)">SU-11274</a></li>
<li><a href="https://en.wikipedia.org/wiki/Tivantinib" title="Tivantinib">Tivantinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Volitinib" class="mw-redirect" title="Volitinib">Volitinib</a></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/wiki/Emibetuzumab" title="Emibetuzumab">Emibetuzumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ficlatuzumab" title="Ficlatuzumab">Ficlatuzumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Flanvotumab" title="Flanvotumab">Flanvotumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Onartuzumab" title="Onartuzumab">Onartuzumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Rilotumumab" title="Rilotumumab">Rilotumumab</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Telisotuzumab&amp;action=edit&amp;redlink=1" class="new" title="Telisotuzumab (page does not exist)">Telisotuzumab</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Telisotuzumab_vedotin&amp;action=edit&amp;redlink=1" class="new" title="Telisotuzumab vedotin (page does not exist)">Telisotuzumab vedotin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Somatomedin_receptor" title="Somatomedin receptor">IGF</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Insulin-like_growth_factor_1_receptor" title="Insulin-like growth factor 1 receptor">IGF-1</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists</i>: <a href="https://en.wikipedia.org/wiki/Des(1-3)IGF-1" title="Des(1-3)IGF-1">des(1-3)IGF-1</a></li>
<li><a href="https://en.wikipedia.org/wiki/Insulin-like_growth_factor_1" title="Insulin-like growth factor 1">Insulin-like growth factor-1 (somatomedin C)</a></li>
<li><a href="https://en.wikipedia.org/wiki/IGF-1_LR3" title="IGF-1 LR3">IGF-1 LR3</a></li>
<li><a href="https://en.wikipedia.org/wiki/Insulin-like_growth_factor_2" title="Insulin-like growth factor 2">Insulin-like growth factor-2 (somatomedin A)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Insulin" title="Insulin">Insulin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Mecasermin" title="Mecasermin">Mecasermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Mecasermin_rinfabate" title="Mecasermin rinfabate">Mecasermin rinfabate</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=BMS-754807&amp;action=edit&amp;redlink=1" class="new" title="BMS-754807 (page does not exist)">BMS-754807</a></li>
<li><a href="https://en.wikipedia.org/wiki/Linsitinib" title="Linsitinib">Linsitinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=NVP-ADW742&amp;action=edit&amp;redlink=1" class="new" title="NVP-ADW742 (page does not exist)">NVP-ADW742</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=NVP-AEW541&amp;action=edit&amp;redlink=1" class="new" title="NVP-AEW541 (page does not exist)">NVP-AEW541</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=OSl-906&amp;action=edit&amp;redlink=1" class="new" title="OSl-906 (page does not exist)">OSl-906</a></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/w/index.php?title=AVE-1642&amp;action=edit&amp;redlink=1" class="new" title="AVE-1642 (page does not exist)">AVE-1642</a></li>
<li><a href="https://en.wikipedia.org/wiki/Cixutumumab" title="Cixutumumab">Cixutumumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dalotuzumab" title="Dalotuzumab">Dalotuzumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Figitumumab" title="Figitumumab">Figitumumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ganitumab" title="Ganitumab">Ganitumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Robatumumab" title="Robatumumab">Robatumumab</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=R1507&amp;action=edit&amp;redlink=1" class="new" title="R1507 (page does not exist)">R1507</a></li>
<li><a href="https://en.wikipedia.org/wiki/Teprotumumab" title="Teprotumumab">Teprotumumab</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Xentuzumab&amp;action=edit&amp;redlink=1" class="new" title="Xentuzumab (page does not exist)">Xentuzumab</a> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Insulin-like_growth_factor_2_receptor" title="Insulin-like growth factor 2 receptor">IGF-2</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists</i>: <a href="https://en.wikipedia.org/wiki/Insulin-like_growth_factor_2" title="Insulin-like growth factor 2">Insulin-like growth factor-2 (somatomedin A)</a></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/wiki/Dusigitumab" title="Dusigitumab">Dusigitumab</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Xentuzumab&amp;action=edit&amp;redlink=1" class="new" title="Xentuzumab (page does not exist)">Xentuzumab</a> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Binding proteins:</i> <a href="https://en.wikipedia.org/wiki/Insulin-like_growth_factor-binding_protein" title="Insulin-like growth factor-binding protein">IGFBP</a> (<a href="https://en.wikipedia.org/wiki/IGFBP1" title="IGFBP1">1</a>, <a href="https://en.wikipedia.org/wiki/IGFBP2" title="IGFBP2">2</a>, <a href="https://en.wikipedia.org/wiki/IGFBP3" title="IGFBP3">3</a>, <a href="https://en.wikipedia.org/wiki/IGFBP4" title="IGFBP4">4</a>, <a href="https://en.wikipedia.org/wiki/IGFBP5" title="IGFBP5">5</a>, <a href="https://en.wikipedia.org/wiki/IGFBP6" title="IGFBP6">6</a>, <a href="https://en.wikipedia.org/wiki/IGFBP7" title="IGFBP7">7</a>)</li></ul>
<ul><li><i>Cleavage products/derivatives with unknown target:</i> <a href="https://en.wikipedia.org/w/index.php?title=Glypromate&amp;action=edit&amp;redlink=1" class="new" title="Glypromate (page does not exist)">Glypromate (GPE, (1-3)IGF-1)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Trofinetide" title="Trofinetide">Trofinetide</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Low-affinity_nerve_growth_factor_receptor" title="Low-affinity nerve growth factor receptor">LNGF (p75<sup>NTR</sup>)</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Brain-derived_neurotrophic_factor" title="Brain-derived neurotrophic factor">BDNF</a></li>
<li><a href="https://en.wikipedia.org/wiki/BNN-20" title="BNN-20">BNN-20</a></li>
<li><a href="https://en.wikipedia.org/wiki/BNN-27" title="BNN-27">BNN-27</a></li>
<li><a href="https://en.wikipedia.org/wiki/Cenegermin" title="Cenegermin">Cenegermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li><a href="https://en.wikipedia.org/wiki/Nerve_growth_factor" title="Nerve growth factor">NGF</a></li>
<li><a href="https://en.wikipedia.org/wiki/Neurotrophin-3" title="Neurotrophin-3">NT-3</a></li>
<li><a href="https://en.wikipedia.org/wiki/Neurotrophin-4" title="Neurotrophin-4">NT-4</a></li></ul>
<ul><li><i>Antagonists:</i> <a href="https://en.wikipedia.org/w/index.php?title=ALE-0540&amp;action=edit&amp;redlink=1" class="new" title="ALE-0540 (page does not exist)">ALE-0540</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=EVT-901&amp;action=edit&amp;redlink=1" class="new" title="EVT-901 (page does not exist)">EVT-901 (SAR-127963)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Testosterone" title="Testosterone">Testosterone</a></li></ul>
<ul><li><i>Antibodies:</i> <i>Against NGF:</i> <a href="https://en.wikipedia.org/w/index.php?title=ABT-110&amp;action=edit&amp;redlink=1" class="new" title="ABT-110 (page does not exist)">ABT-110 (PG110)</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=ASP-6294&amp;action=edit&amp;redlink=1" class="new" title="ASP-6294 (page does not exist)">ASP-6294</a></li>
<li><a href="https://en.wikipedia.org/wiki/Fasinumab" title="Fasinumab">Fasinumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Frunevetmab" title="Frunevetmab">Frunevetmab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Fulranumab" title="Fulranumab">Fulranumab</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=MEDI-578&amp;action=edit&amp;redlink=1" class="new" title="MEDI-578 (page does not exist)">MEDI-578</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Ranevetmab&amp;action=edit&amp;redlink=1" class="new" title="Ranevetmab (page does not exist)">Ranevetmab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Tanezumab" title="Tanezumab">Tanezumab</a></li></ul>
<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <a href="https://en.wikipedia.org/w/index.php?title=RBM-004&amp;action=edit&amp;redlink=1" class="new" title="RBM-004 (page does not exist)">RBM-004</a></li></ul>
<ul><li><i>Decoy receptors:</i> <a href="https://en.wikipedia.org/w/index.php?title=LEVI-04&amp;action=edit&amp;redlink=1" class="new" title="LEVI-04 (page does not exist)">LEVI-04 (p75<sup>NTR</sup>-Fc)</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Platelet-derived_growth_factor_receptor" title="Platelet-derived growth factor receptor">PDGF</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Becaplermin" title="Becaplermin">Becaplermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Platelet-derived_growth_factor" title="Platelet-derived growth factor">Platelet-derived growth factor</a> (<a href="https://en.wikipedia.org/wiki/PDGFA" title="PDGFA">A</a>, <a href="https://en.wikipedia.org/wiki/PDGFB" title="PDGFB">B</a>, <a href="https://en.wikipedia.org/wiki/PDGFC" title="PDGFC">C</a>, <a href="https://en.wikipedia.org/wiki/PDGFD" title="PDGFD">D</a>)</li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=Agerafenib&amp;action=edit&amp;redlink=1" class="new" title="Agerafenib (page does not exist)">Agerafenib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Avapritinib" title="Avapritinib">Avapritinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Axitinib" title="Axitinib">Axitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Crenolanib" title="Crenolanib">Crenolanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Imatinib" title="Imatinib">Imatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Lenvatinib" title="Lenvatinib">Lenvatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Masitinib" title="Masitinib">Masitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Motesanib" title="Motesanib">Motesanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Nintedanib" title="Nintedanib">Nintedanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Radotinib" title="Radotinib">Radotinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Quizartinib" title="Quizartinib">Quizartinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ripretinib" title="Ripretinib">Ripretinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Toceranib" title="Toceranib">Toceranib</a></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/wiki/Olaratumab" title="Olaratumab">Olaratumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ramucirumab" title="Ramucirumab">Ramucirumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Tovetumab" title="Tovetumab">Tovetumab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/RET_proto-oncogene" title="RET proto-oncogene">RET (GFL)</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/GFRα1" class="mw-redirect" title="GFRα1">GFRα1</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Glial_cell_line-derived_neurotrophic_factor" title="Glial cell line-derived neurotrophic factor">Glial cell line-derived neurotrophic factor (GDNF)</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Liatermin&amp;action=edit&amp;redlink=1" class="new" title="Liatermin (page does not exist)">Liatermin</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/GFRα2" class="mw-redirect" title="GFRα2">GFRα2</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Neurturin" title="Neurturin">Neurturin (NRTN)</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/GFRα3" class="mw-redirect" title="GFRα3">GFRα3</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Artemin" title="Artemin">Artemin (ARTN)</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/GFRα4" class="mw-redirect" title="GFRα4">GFRα4</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Persephin" title="Persephin">Persephin (PSPN)</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=Agerafenib&amp;action=edit&amp;redlink=1" class="new" title="Agerafenib (page does not exist)">Agerafenib</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/CD117" class="mw-redirect" title="CD117">SCF (c-Kit)</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Ancestim" title="Ancestim">Ancestim</a></li>
<li><a href="https://en.wikipedia.org/wiki/Stem_cell_factor" title="Stem cell factor">Stem cell factor</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=Agerafenib&amp;action=edit&amp;redlink=1" class="new" title="Agerafenib (page does not exist)">Agerafenib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Axitinib" title="Axitinib">Axitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Imatinib" title="Imatinib">Imatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Masitinib" title="Masitinib">Masitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Nilotinib" title="Nilotinib">Nilotinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Quizartinib" title="Quizartinib">Quizartinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Toceranib" title="Toceranib">Toceranib</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Transforming_growth_factor_beta_receptor" class="mw-redirect" title="Transforming growth factor beta receptor">TGFβ</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li>See <a href="https://en.wikipedia.org/wiki/Template:TGFβ_receptor_superfamily_modulators" title="Template:TGFβ receptor superfamily modulators">here</a> instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Trk_receptor" title="Trk receptor">Trk</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/TrkA_receptor" class="mw-redirect" title="TrkA receptor">TrkA</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li><a href="https://en.wikipedia.org/wiki/BNN-20" title="BNN-20">BNN-20</a></li>
<li><a href="https://en.wikipedia.org/wiki/BNN-27" title="BNN-27">BNN-27</a></li>
<li><a href="https://en.wikipedia.org/wiki/Cenegermin" title="Cenegermin">Cenegermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Gambogic_amide&amp;action=edit&amp;redlink=1" class="new" title="Gambogic amide (page does not exist)">Gambogic amide</a></li>
<li><a href="https://en.wikipedia.org/wiki/Nerve_growth_factor" title="Nerve growth factor">NGF</a></li>
<li><a href="https://en.wikipedia.org/wiki/Tavilermide" title="Tavilermide">Tavilermide</a></li></ul>
<ul><li><i>Antagonists:</i> <a href="https://en.wikipedia.org/w/index.php?title=ALE-0540&amp;action=edit&amp;redlink=1" class="new" title="ALE-0540 (page does not exist)">ALE-0540</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><a href="https://en.wikipedia.org/wiki/FX007" class="mw-redirect" title="FX007">FX007</a></li>
<li><a href="https://en.wikipedia.org/wiki/Testosterone" title="Testosterone">Testosterone</a></li></ul>
<ul><li><i>Negative allosteric modulators:</i> <a href="https://en.wikipedia.org/w/index.php?title=VM-902A&amp;action=edit&amp;redlink=1" class="new" title="VM-902A (page does not exist)">VM-902A</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=Altiratinib&amp;action=edit&amp;redlink=1" class="new" title="Altiratinib (page does not exist)">Altiratinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=AZD-6918&amp;action=edit&amp;redlink=1" class="new" title="AZD-6918 (page does not exist)">AZD-6918</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=CE-245677&amp;action=edit&amp;redlink=1" class="new" title="CE-245677 (page does not exist)">CE-245677</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=CH-7057288&amp;action=edit&amp;redlink=1" class="new" title="CH-7057288 (page does not exist)">CH-7057288</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=DS-6051&amp;action=edit&amp;redlink=1" class="new" title="DS-6051 (page does not exist)">DS-6051</a></li>
<li><a href="https://en.wikipedia.org/wiki/Entrectinib" title="Entrectinib">Entrectinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=GZ-389988&amp;action=edit&amp;redlink=1" class="new" title="GZ-389988 (page does not exist)">GZ-389988</a></li>
<li><a href="https://en.wikipedia.org/wiki/K252a" title="K252a">K252a</a></li>
<li><a href="https://en.wikipedia.org/wiki/Larotrectinib" title="Larotrectinib">Larotrectinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Lestaurtinib" title="Lestaurtinib">Lestaurtinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Milciclib&amp;action=edit&amp;redlink=1" class="new" title="Milciclib (page does not exist)">Milciclib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=ONO-4474&amp;action=edit&amp;redlink=1" class="new" title="ONO-4474 (page does not exist)">ONO-4474</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=ONO-5390556&amp;action=edit&amp;redlink=1" class="new" title="ONO-5390556 (page does not exist)">ONO-5390556</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=PLX-7486&amp;action=edit&amp;redlink=1" class="new" title="PLX-7486 (page does not exist)">PLX-7486</a></li>
<li><a href="https://en.wikipedia.org/wiki/Rebastinib" class="mw-redirect" title="Rebastinib">Rebastinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=SNA-120&amp;action=edit&amp;redlink=1" class="new" title="SNA-120 (page does not exist)">SNA-120 (pegylated K252a)</a>)</li></ul>
<ul><li><i>Antibodies:</i> <i>Against TrkA:</i> <a href="https://en.wikipedia.org/w/index.php?title=GBR-900&amp;action=edit&amp;redlink=1" class="new" title="GBR-900 (page does not exist)">GBR-900</a>; <i>Against NGF:</i> <a href="https://en.wikipedia.org/w/index.php?title=ABT-110&amp;action=edit&amp;redlink=1" class="new" title="ABT-110 (page does not exist)">ABT-110 (PG110)</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=ASP-6294&amp;action=edit&amp;redlink=1" class="new" title="ASP-6294 (page does not exist)">ASP-6294</a></li>
<li><a href="https://en.wikipedia.org/wiki/Fasinumab" title="Fasinumab">Fasinumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Frunevetmab" title="Frunevetmab">Frunevetmab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Fulranumab" title="Fulranumab">Fulranumab</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=MEDI-578&amp;action=edit&amp;redlink=1" class="new" title="MEDI-578 (page does not exist)">MEDI-578</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Ranevetmab&amp;action=edit&amp;redlink=1" class="new" title="Ranevetmab (page does not exist)">Ranevetmab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Tanezumab" title="Tanezumab">Tanezumab</a></li></ul>
<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <a href="https://en.wikipedia.org/w/index.php?title=RBM-004&amp;action=edit&amp;redlink=1" class="new" title="RBM-004 (page does not exist)">RBM-004</a></li></ul>
<ul><li><i>Decoy receptors:</i> <a href="https://en.wikipedia.org/w/index.php?title=ReN-1820&amp;action=edit&amp;redlink=1" class="new" title="ReN-1820 (page does not exist)">ReN-1820 (TrkAd5)</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/TrkB_receptor" class="mw-redirect" title="TrkB receptor">TrkB</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/w/index.php?title=3,7-Dihydroxyflavone&amp;action=edit&amp;redlink=1" class="new" title="3,7-Dihydroxyflavone (page does not exist)">3,7-DHF</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=3,7,8,2%27-Tetrahydroxyflavone&amp;action=edit&amp;redlink=1" class="new" title="3,7,8,2&#39;-Tetrahydroxyflavone (page does not exist)">3,7,8,2'-THF</a></li>
<li><a href="https://en.wikipedia.org/wiki/4%27-Dimethylamino-7,8-dihydroxyflavone" class="mw-redirect" title="4&#39;-Dimethylamino-7,8-dihydroxyflavone">4'-DMA-7,8-DHF</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=7,3%E2%80%B2-Dihydroxyflavone&amp;action=edit&amp;redlink=1" class="new" title="7,3′-Dihydroxyflavone (page does not exist)">7,3'-DHF</a></li>
<li><a href="https://en.wikipedia.org/wiki/7,8-Dihydroxyflavone" class="mw-redirect" title="7,8-Dihydroxyflavone">7,8-DHF</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=7,8,2%27-Trihydroxyflavone&amp;action=edit&amp;redlink=1" class="new" title="7,8,2&#39;-Trihydroxyflavone (page does not exist)">7,8,2'-THF</a></li>
<li><a href="https://en.wikipedia.org/wiki/7,8,3%27-Trihydroxyflavone" title="7,8,3&#39;-Trihydroxyflavone">7,8,3'-THF</a></li>
<li><a href="https://en.wikipedia.org/wiki/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li><a href="https://en.wikipedia.org/wiki/Brain-derived_neurotrophic_factor" title="Brain-derived neurotrophic factor">BDNF</a></li>
<li><a href="https://en.wikipedia.org/wiki/BNN-20" title="BNN-20">BNN-20</a></li>
<li><a href="https://en.wikipedia.org/wiki/Deoxygedunin" title="Deoxygedunin">Deoxygedunin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Deprenyl" class="mw-redirect" title="Deprenyl">Deprenyl</a></li>
<li><a href="https://en.wikipedia.org/wiki/Diosmetin" title="Diosmetin">Diosmetin</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=DMAQ-B1&amp;action=edit&amp;redlink=1" class="new" title="DMAQ-B1 (page does not exist)">DMAQ-B1</a></li>
<li><a href="https://en.wikipedia.org/wiki/HIOC" title="HIOC">HIOC</a></li>
<li><a href="https://en.wikipedia.org/wiki/LM22A-4" title="LM22A-4">LM22A-4</a></li>
<li><a href="https://en.wikipedia.org/wiki/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Neurotrophin-3" title="Neurotrophin-3">NT-3</a></li>
<li><a href="https://en.wikipedia.org/wiki/Neurotrophin-4" title="Neurotrophin-4">NT-4</a></li>
<li><a href="https://en.wikipedia.org/wiki/Norwogonin" title="Norwogonin">Norwogonin (5,7,8-THF)</a></li>
<li><a href="https://en.wikipedia.org/wiki/R7_(drug)" title="R7 (drug)">R7</a></li>
<li><a href="https://en.wikipedia.org/wiki/R13_(drug)" title="R13 (drug)">R13</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=TDP6&amp;action=edit&amp;redlink=1" class="new" title="TDP6 (page does not exist)">TDP6</a></li></ul>
<ul><li><i>Antagonists:</i> <a href="https://en.wikipedia.org/wiki/ANA-12" title="ANA-12">ANA-12</a></li>
<li><a href="https://en.wikipedia.org/wiki/Cyclotraxin_B" title="Cyclotraxin B">Cyclotraxin B</a></li>
<li><a href="https://en.wikipedia.org/wiki/Gossypetin" title="Gossypetin">Gossypetin (3,5,7,8,3',4'-HHF)</a></li></ul>
<ul><li><i>Ligands:</i> <a href="https://en.wikipedia.org/wiki/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=Altiratinib&amp;action=edit&amp;redlink=1" class="new" title="Altiratinib (page does not exist)">Altiratinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=AZD-6918&amp;action=edit&amp;redlink=1" class="new" title="AZD-6918 (page does not exist)">AZD-6918</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=CE-245677&amp;action=edit&amp;redlink=1" class="new" title="CE-245677 (page does not exist)">CE-245677</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=CH-7057288&amp;action=edit&amp;redlink=1" class="new" title="CH-7057288 (page does not exist)">CH-7057288</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=DS-6051&amp;action=edit&amp;redlink=1" class="new" title="DS-6051 (page does not exist)">DS-6051</a></li>
<li><a href="https://en.wikipedia.org/wiki/Entrectinib" title="Entrectinib">Entrectinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=GZ-389988&amp;action=edit&amp;redlink=1" class="new" title="GZ-389988 (page does not exist)">GZ-389988</a></li>
<li><a href="https://en.wikipedia.org/wiki/K252a" title="K252a">K252a</a></li>
<li><a href="https://en.wikipedia.org/wiki/Larotrectinib" title="Larotrectinib">Larotrectinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Lestaurtinib" title="Lestaurtinib">Lestaurtinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=ONO-4474&amp;action=edit&amp;redlink=1" class="new" title="ONO-4474 (page does not exist)">ONO-4474</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=ONO-5390556&amp;action=edit&amp;redlink=1" class="new" title="ONO-5390556 (page does not exist)">ONO-5390556</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=PLX-7486&amp;action=edit&amp;redlink=1" class="new" title="PLX-7486 (page does not exist)">PLX-7486</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/TrkC_receptor" class="mw-redirect" title="TrkC receptor">TrkC</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/BNN-20" title="BNN-20">BNN-20</a></li>
<li><a href="https://en.wikipedia.org/wiki/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="https://en.wikipedia.org/wiki/Neurotrophin-3" title="Neurotrophin-3">NT-3</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=Altiratinib&amp;action=edit&amp;redlink=1" class="new" title="Altiratinib (page does not exist)">Altiratinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=AZD-6918&amp;action=edit&amp;redlink=1" class="new" title="AZD-6918 (page does not exist)">AZD-6918</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=CE-245677&amp;action=edit&amp;redlink=1" class="new" title="CE-245677 (page does not exist)">CE-245677</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=CH-7057288&amp;action=edit&amp;redlink=1" class="new" title="CH-7057288 (page does not exist)">CH-7057288</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=DS-6051&amp;action=edit&amp;redlink=1" class="new" title="DS-6051 (page does not exist)">DS-6051</a></li>
<li><a href="https://en.wikipedia.org/wiki/Entrectinib" title="Entrectinib">Entrectinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=GZ-389988&amp;action=edit&amp;redlink=1" class="new" title="GZ-389988 (page does not exist)">GZ-389988</a></li>
<li><a href="https://en.wikipedia.org/wiki/K252a" title="K252a">K252a</a></li>
<li><a href="https://en.wikipedia.org/wiki/Larotrectinib" title="Larotrectinib">Larotrectinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Lestaurtinib" title="Lestaurtinib">Lestaurtinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=ONO-4474&amp;action=edit&amp;redlink=1" class="new" title="ONO-4474 (page does not exist)">ONO-4474</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=ONO-5390556&amp;action=edit&amp;redlink=1" class="new" title="ONO-5390556 (page does not exist)">ONO-5390556</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=PLX-7486&amp;action=edit&amp;redlink=1" class="new" title="PLX-7486 (page does not exist)">PLX-7486</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor_receptor" class="mw-redirect" title="Vascular endothelial growth factor receptor">VEGF</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Agonists:</i> <a href="https://en.wikipedia.org/wiki/Placental_growth_factor" title="Placental growth factor">Placental growth factor (PGF)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ripretinib" title="Ripretinib">Ripretinib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Telbermin&amp;action=edit&amp;redlink=1" class="new" title="Telbermin (page does not exist)">Telbermin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor" title="Vascular endothelial growth factor">VEGF</a> (<a href="https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor_A" title="Vascular endothelial growth factor A">A</a>, <a href="https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor_B" title="Vascular endothelial growth factor B">B</a>, <a href="https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor_C" title="Vascular endothelial growth factor C">C</a>, <a href="https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor_D" class="mw-redirect" title="Vascular endothelial growth factor D">D (FIGF)</a>)</li></ul>
<ul><li><i>Allosteric modulators:</i> <a href="https://en.wikipedia.org/wiki/Cyclotraxin_B" title="Cyclotraxin B">Cyclotraxin B</a></li></ul>
<ul><li><i>Kinase inhibitors:</i> <a href="https://en.wikipedia.org/w/index.php?title=Agerafenib&amp;action=edit&amp;redlink=1" class="new" title="Agerafenib (page does not exist)">Agerafenib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=Altiratinib&amp;action=edit&amp;redlink=1" class="new" title="Altiratinib (page does not exist)">Altiratinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Axitinib" title="Axitinib">Axitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Cabozantinib" title="Cabozantinib">Cabozantinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Cediranib" title="Cediranib">Cediranib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Lenvatinib" title="Lenvatinib">Lenvatinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Motesanib" title="Motesanib">Motesanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Nintedanib" title="Nintedanib">Nintedanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Pegaptanib" title="Pegaptanib">Pegaptanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Rebastinib" class="mw-redirect" title="Rebastinib">Rebastinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Regorafenib" title="Regorafenib">Regorafenib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Semaxanib" title="Semaxanib">Semaxanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Toceranib" title="Toceranib">Toceranib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Tivozanib" title="Tivozanib">Tivozanib</a></li>
<li><a href="https://en.wikipedia.org/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li>
<li><a href="https://en.wikipedia.org/w/index.php?title=WHI-P_154&amp;action=edit&amp;redlink=1" class="new" title="WHI-P 154 (page does not exist)">WHI-P 154</a></li></ul>
<ul><li><i>Antibodies:</i> <a href="https://en.wikipedia.org/wiki/Alacizumab_pegol" title="Alacizumab pegol">Alacizumab pegol</a></li>
<li><a href="https://en.wikipedia.org/wiki/Bevacizumab" title="Bevacizumab">Bevacizumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Icrucumab" title="Icrucumab">Icrucumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ramucirumab" title="Ramucirumab">Ramucirumab</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ranibizumab" title="Ranibizumab">Ranibizumab</a></li></ul>
<ul><li><i>Decoy receptors:</i> <a href="https://en.wikipedia.org/wiki/Aflibercept" title="Aflibercept">Aflibercept</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em">
<ul><li><i>Additional growth factors:</i> <a href="https://en.wikipedia.org/wiki/Adrenomedullin" title="Adrenomedullin">Adrenomedullin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Colony-stimulating_factor" title="Colony-stimulating factor">Colony-stimulating factors</a> (see <a href="https://en.wikipedia.org/wiki/Template:Cytokine_receptor_modulators" title="Template:Cytokine receptor modulators">here</a> instead)</li>
<li><a href="https://en.wikipedia.org/wiki/Connective_tissue_growth_factor" class="mw-redirect" title="Connective tissue growth factor">Connective tissue growth factor (CTGF)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ephrin" title="Ephrin">Ephrins</a> (<a href="https://en.wikipedia.org/wiki/EFNA1" class="mw-redirect" title="EFNA1">A1</a>, <a href="https://en.wikipedia.org/wiki/EFNA2" class="mw-redirect" title="EFNA2">A2</a>, <a href="https://en.wikipedia.org/wiki/EFNA3" class="mw-redirect" title="EFNA3">A3</a>, <a href="https://en.wikipedia.org/wiki/EFNA4" class="mw-redirect" title="EFNA4">A4</a>, <a href="https://en.wikipedia.org/wiki/EFNA5" class="mw-redirect" title="EFNA5">A5</a>, <a href="https://en.wikipedia.org/wiki/EFNB1" class="mw-redirect" title="EFNB1">B1</a>, <a href="https://en.wikipedia.org/wiki/EFNB2" class="mw-redirect" title="EFNB2">B2</a>, <a href="https://en.wikipedia.org/wiki/EFNB3" class="mw-redirect" title="EFNB3">B3</a>)</li>
<li><a href="https://en.wikipedia.org/wiki/Erythropoietin" title="Erythropoietin">Erythropoietin</a> (see <a href="https://en.wikipedia.org/wiki/Template:Cytokine_receptor_modulators" title="Template:Cytokine receptor modulators">here</a> instead)</li>
<li><a href="https://en.wikipedia.org/wiki/Glucose-6-phosphate_isomerase" title="Glucose-6-phosphate isomerase">Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Glia_maturation_factor" title="Glia maturation factor">Glia maturation factor (GMF)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Hepatoma-derived_growth_factor" title="Hepatoma-derived growth factor">Hepatoma-derived growth factor (HDGF)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Interleukin" title="Interleukin">Interleukins</a>/<a href="https://en.wikipedia.org/wiki/T-cell_growth_factor" title="T-cell growth factor">T-cell growth factors</a> (see <a href="https://en.wikipedia.org/wiki/Template:Cytokine_receptor_modulators" title="Template:Cytokine receptor modulators">here</a> instead)</li>
<li><a href="https://en.wikipedia.org/wiki/Leukemia_inhibitory_factor" title="Leukemia inhibitory factor">Leukemia inhibitory factor (LIF)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Macrophage-stimulating_protein" class="mw-redirect" title="Macrophage-stimulating protein">Macrophage-stimulating protein (MSP; HLP, HGFLP)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Midkine" title="Midkine">Midkine (NEGF2)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Migration-stimulating_factor" class="mw-redirect" title="Migration-stimulating factor">Migration-stimulating factor (MSF; PRG4)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Oncomodulin" title="Oncomodulin">Oncomodulin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Pituitary_adenylate_cyclase-activating_peptide" title="Pituitary adenylate cyclase-activating peptide">Pituitary adenylate cyclase-activating peptide (PACAP)</a></li>
<li><a href="https://en.wikipedia.org/wiki/Pleiotrophin" title="Pleiotrophin">Pleiotrophin</a></li>
<li><a href="https://en.wikipedia.org/wiki/Renalase" title="Renalase">Renalase</a></li>
<li><a href="https://en.wikipedia.org/wiki/Thrombopoietin" title="Thrombopoietin">Thrombopoietin</a> (see <a href="https://en.wikipedia.org/wiki/Template:Cytokine_receptor_modulators" title="Template:Cytokine receptor modulators">here</a> instead)</li>
<li><a href="https://en.wikipedia.org/wiki/Wnt_signaling_pathway" title="Wnt signaling pathway">Wnt signaling proteins</a></li></ul>
<ul><li><i>Additional growth factor receptor modulators:</i> <a href="https://en.wikipedia.org/wiki/Cerebrolysin" title="Cerebrolysin">Cerebrolysin</a> (neurotrophin mixture)</li></ul>
</div></td></tr></tbody></table></div>
<!-- 
NewPP limit report
Parsed by mw1451
Cached time: 20220505180528
Cache expiry: 3600
Reduced expiry: true
Complications: [vary‐revision‐sha1]
CPU time usage: 0.833 seconds
Real time usage: 0.975 seconds
Preprocessor visited node count: 4192/1000000
Post‐expand include size: 200128/2097152 bytes
Template argument size: 4620/2097152 bytes
Highest expansion depth: 22/100
Expensive parser function count: 5/500
Unstrip recursion depth: 1/20
Unstrip post‐expand size: 107070/5000000 bytes
Lua time usage: 0.398/10.000 seconds
Lua memory usage: 6716933/52428800 bytes
Number of Wikibase entities loaded: 0/400
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  702.092      1 -total
 47.52%  333.643      1 Template:Reflist
 20.50%  143.962      6 Template:Cite_journal
 17.11%  120.146     16 Template:Citation
 12.92%   90.743      7 Template:Navbox
 10.75%   75.467      2 Template:When
 10.71%   75.196      4 Template:Update_after
  9.81%   68.899      1 Template:Drug_design
  7.65%   53.683      2 Template:Fix
  7.18%   50.394      4 Template:Update_inline_span
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:33238902-0!canonical and timestamp 20220505180527 and revision id 1079883091. Serialized with JSON.
 -->
</div><noscript><img src="http://en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript>
<div class="printfooter">Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;oldid=1079883091">https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;oldid=1079883091</a>"</div></div>
		<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="https://en.wikipedia.org/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="https://en.wikipedia.org/wiki/Category:Cancer_research" title="Category:Cancer research">Cancer research</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Protein_kinase_inhibitors" title="Category:Protein kinase inhibitors">Protein kinase inhibitors</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Breakthrough_therapy" title="Category:Breakthrough therapy">Breakthrough therapy</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Orphan_drugs" title="Category:Orphan drugs">Orphan drugs</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="https://en.wikipedia.org/wiki/Category:All_articles_with_vague_or_ambiguous_time" title="Category:All articles with vague or ambiguous time">All articles with vague or ambiguous time</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Vague_or_ambiguous_time_from_November_2020" title="Category:Vague or ambiguous time from November 2020">Vague or ambiguous time from November 2020</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Wikipedia_articles_in_need_of_updating_from_December_2011" title="Category:Wikipedia articles in need of updating from December 2011">Wikipedia articles in need of updating from December 2011</a></li><li><a href="https://en.wikipedia.org/wiki/Category:All_Wikipedia_articles_in_need_of_updating" title="Category:All Wikipedia articles in need of updating">All Wikipedia articles in need of updating</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Articles_contradicting_other_articles" title="Category:Articles contradicting other articles">Articles contradicting other articles</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Articles_containing_potentially_dated_statements_from_2010" title="Category:Articles containing potentially dated statements from 2010">Articles containing potentially dated statements from 2010</a></li><li><a href="https://en.wikipedia.org/wiki/Category:All_articles_containing_potentially_dated_statements" title="Category:All articles containing potentially dated statements">All articles containing potentially dated statements</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Articles_to_be_expanded_from_June_2018" title="Category:Articles to be expanded from June 2018">Articles to be expanded from June 2018</a></li><li><a href="https://en.wikipedia.org/wiki/Category:All_articles_to_be_expanded" title="Category:All articles to be expanded">All articles to be expanded</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Articles_using_small_message_boxes" title="Category:Articles using small message boxes">Articles using small message boxes</a></li><li><a href="https://en.wikipedia.org/wiki/Category:Articles_with_incomplete_citations_from_November_2020" title="Category:Articles with incomplete citations from November 2020">Articles with incomplete citations from November 2020</a></li><li><a href="https://en.wikipedia.org/wiki/Category:All_articles_with_incomplete_citations" title="Category:All articles with incomplete citations">All articles with incomplete citations</a></li><li><a href="https://en.wikipedia.org/wiki/Category:All_pages_needing_cleanup" title="Category:All pages needing cleanup">All pages needing cleanup</a></li></ul></div></div>
	</div>
</div>
<div id='mw-data-after-content'>
	<div class="read-more-container"></div>
</div>

<div id="mw-navigation">
	<h2>Navigation menu</h2>
	<div id="mw-head">
		
<nav id="p-personal" class="mw-portlet mw-portlet-personal vector-user-menu-legacy vector-menu" aria-labelledby="p-personal-label" role="navigation" 
	 >
	<label id="p-personal-label" aria-label="" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">Personal tools</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"><li id="pt-anonuserpage" class="mw-list-item"><span title="The user page for the IP address you are editing as">Not logged in</span></li><li id="pt-anontalk" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n"><span>Talk</span></a></li><li id="pt-anoncontribs" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y"><span>Contributions</span></a></li><li id="pt-createaccount" class="mw-list-item"><a href="https://en.wikipedia.org/w/index.php?title=Special:CreateAccount&amp;returnto=C-Met+inhibitor" title="You are encouraged to create an account and log in; however, it is not mandatory"><span>Create account</span></a></li><li id="pt-login" class="mw-list-item"><a href="https://en.wikipedia.org/w/index.php?title=Special:UserLogin&amp;returnto=C-Met+inhibitor" title="You&#039;re encouraged to log in; however, it&#039;s not mandatory. [o]" accesskey="o"><span>Log in</span></a></li></ul>
		
	</div>
</nav>

		<div id="left-navigation">
			
<nav id="p-namespaces" class="mw-portlet mw-portlet-namespaces vector-menu vector-menu-tabs" aria-labelledby="p-namespaces-label" role="navigation" 
	 >
	<label id="p-namespaces-label" aria-label="" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">Namespaces</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"><li id="ca-nstab-main" class="selected mw-list-item"><a href="https://en.wikipedia.org/wiki/C-Met_inhibitor" title="View the content page [c]" accesskey="c"><span>Article</span></a></li><li id="ca-talk" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Talk:C-Met_inhibitor" rel="discussion" title="Discuss improvements to the content page [t]" accesskey="t"><span>Talk</span></a></li></ul>
		
	</div>
</nav>

			
<nav id="p-variants" class="mw-portlet mw-portlet-variants emptyPortlet vector-menu-dropdown-noicon vector-menu vector-menu-dropdown" aria-labelledby="p-variants-label" role="navigation" 
	 >
	<input type="checkbox"
		id="p-variants-checkbox"
		role="button"
		aria-haspopup="true"
		data-event-name="ui.dropdown-p-variants"
		class="vector-menu-checkbox" aria-labelledby="p-variants-label" />
	<label id="p-variants-label" aria-label="Change language variant" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">English</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"></ul>
		
	</div>
</nav>

		</div>
		<div id="right-navigation">
			
<nav id="p-views" class="mw-portlet mw-portlet-views vector-menu vector-menu-tabs" aria-labelledby="p-views-label" role="navigation" 
	 >
	<label id="p-views-label" aria-label="" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">Views</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"><li id="ca-view" class="selected mw-list-item"><a href="https://en.wikipedia.org/wiki/C-Met_inhibitor"><span>Read</span></a></li><li id="ca-edit" class="mw-list-item"><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=edit" title="Edit this page [e]" accesskey="e"><span>Edit</span></a></li><li id="ca-history" class="mw-list-item"><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=history" title="Past revisions of this page [h]" accesskey="h"><span>View history</span></a></li></ul>
		
	</div>
</nav>

			
<nav id="p-cactions" class="mw-portlet mw-portlet-cactions emptyPortlet vector-menu-dropdown-noicon vector-menu vector-menu-dropdown" aria-labelledby="p-cactions-label" role="navigation"  title="More options"
	 >
	<input type="checkbox"
		id="p-cactions-checkbox"
		role="button"
		aria-haspopup="true"
		data-event-name="ui.dropdown-p-cactions"
		class="vector-menu-checkbox" aria-labelledby="p-cactions-label" />
	<label id="p-cactions-label" aria-label="" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">More</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"></ul>
		
	</div>
</nav>

			
<div id="p-search" role="search" class="vector-search-box-vue  vector-search-box-show-thumbnail vector-search-box-auto-expand-width vector-search-box">
	<div>
			<h3 >
				<label for="searchInput">Search</label>
			</h3>
		<form action="https://en.wikipedia.org/w/index.php" id="searchform"
			class="vector-search-box-form">
			<div id="simpleSearch"
				class="vector-search-box-inner"
				 data-search-loc="header-navigation">
				<input class="vector-search-box-input"
					 type="search" name="search" placeholder="Search Wikipedia" aria-label="Search Wikipedia" autocapitalize="sentences" title="Search Wikipedia [f]" accesskey="f" id="searchInput"
				/>
				<input type="hidden" name="title" value="Special:Search"/>
				<input id="mw-searchButton"
					 class="searchButton mw-fallbackSearchButton" type="submit" name="fulltext" title="Search Wikipedia for this text" value="Search" />
				<input id="searchButton"
					 class="searchButton" type="submit" name="go" title="Go to a page with this exact name if it exists" value="Go" />
			</div>
		</form>
	</div>
</div>

		</div>
	</div>
	

<div id="mw-panel">
	<div id="p-logo" role="banner">
		<a class="mw-wiki-logo" href="https://en.wikipedia.org/wiki/Main_Page"
			title="Visit the main page"></a>
	</div>
	
<nav id="p-navigation" class="mw-portlet mw-portlet-navigation vector-menu vector-menu-portal portal" aria-labelledby="p-navigation-label" role="navigation" 
	 >
	<label id="p-navigation-label" aria-label="" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">Navigation</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"><li id="n-mainpage-description" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Main_Page" icon="home" title="Visit the main page [z]" accesskey="z"><span>Main page</span></a></li><li id="n-contents" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Wikipedia:Contents" title="Guides to browsing Wikipedia"><span>Contents</span></a></li><li id="n-currentevents" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Portal:Current_events" title="Articles related to current events"><span>Current events</span></a></li><li id="n-randompage" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Special:Random" icon="die" title="Visit a randomly selected article [x]" accesskey="x"><span>Random article</span></a></li><li id="n-aboutsite" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Wikipedia:About" title="Learn about Wikipedia and how it works"><span>About Wikipedia</span></a></li><li id="n-contactpage" class="mw-list-item"><a href="http://en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia"><span>Contact us</span></a></li><li id="n-sitesupport" class="mw-list-item"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us by donating to the Wikimedia Foundation"><span>Donate</span></a></li></ul>
		
	</div>
</nav>

	
<nav id="p-interaction" class="mw-portlet mw-portlet-interaction vector-menu vector-menu-portal portal" aria-labelledby="p-interaction-label" role="navigation" 
	 >
	<label id="p-interaction-label" aria-label="" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">Contribute</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"><li id="n-help" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Help:Contents" icon="help" title="Guidance on how to use and edit Wikipedia"><span>Help</span></a></li><li id="n-introduction" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Help:Introduction" title="Learn how to edit Wikipedia"><span>Learn to edit</span></a></li><li id="n-portal" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Wikipedia:Community_portal" title="The hub for editors"><span>Community portal</span></a></li><li id="n-recentchanges" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Special:RecentChanges" icon="recentChanges" title="A list of recent changes to Wikipedia [r]" accesskey="r"><span>Recent changes</span></a></li><li id="n-upload" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Wikipedia:File_Upload_Wizard" title="Add images or other media for use on Wikipedia"><span>Upload file</span></a></li></ul>
		
	</div>
</nav>

<nav id="p-tb" class="mw-portlet mw-portlet-tb vector-menu vector-menu-portal portal" aria-labelledby="p-tb-label" role="navigation" 
	 >
	<label id="p-tb-label" aria-label="" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">Tools</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"><li id="t-whatlinkshere" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Special:WhatLinksHere/C-Met_inhibitor" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j"><span>What links here</span></a></li><li id="t-recentchangeslinked" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Special:RecentChangesLinked/C-Met_inhibitor" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k"><span>Related changes</span></a></li><li id="t-upload" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u"><span>Upload file</span></a></li><li id="t-specialpages" class="mw-list-item"><a href="https://en.wikipedia.org/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q"><span>Special pages</span></a></li><li id="t-permalink" class="mw-list-item"><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;oldid=1079883091" title="Permanent link to this revision of this page"><span>Permanent link</span></a></li><li id="t-info" class="mw-list-item"><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;action=info" title="More information about this page"><span>Page information</span></a></li><li id="t-cite" class="mw-list-item"><a href="https://en.wikipedia.org/w/index.php?title=Special:CiteThisPage&amp;page=C-Met_inhibitor&amp;id=1079883091&amp;wpFormIdentifier=titleform" title="Information on how to cite this page"><span>Cite this page</span></a></li><li id="t-wikibase" class="mw-list-item"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q5005894" title="Structured data on this page hosted by Wikidata [g]" accesskey="g"><span>Wikidata item</span></a></li></ul>
		
	</div>
</nav>

<nav id="p-coll-print_export" class="mw-portlet mw-portlet-coll-print_export vector-menu vector-menu-portal portal" aria-labelledby="p-coll-print_export-label" role="navigation" 
	 >
	<label id="p-coll-print_export-label" aria-label="" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">Print/export</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"><li id="coll-download-as-rl" class="mw-list-item"><a href="https://en.wikipedia.org/w/index.php?title=Special:DownloadAsPdf&amp;page=C-Met_inhibitor&amp;action=show-download-screen" title="Download this page as a PDF file"><span>Download as PDF</span></a></li><li id="t-print" class="mw-list-item"><a href="https://en.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;printable=yes" title="Printable version of this page [p]" accesskey="p"><span>Printable version</span></a></li></ul>
		
	</div>
</nav>

	
<nav id="p-lang" class="mw-portlet mw-portlet-lang vector-menu vector-menu-portal portal" aria-labelledby="p-lang-label" role="navigation" 
	 >
	<label id="p-lang-label" aria-label="" class="vector-menu-heading "  >
		<span class="vector-menu-heading-label">Languages</span>
	</label>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list"></ul>
		<div class="after-portlet after-portlet-lang"><span class="uls-after-portlet-link"></span><span class="wb-langlinks-add wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q5005894#sitelinks-wikipedia" title="Add interlanguage links" class="wbc-editpage">Add links</a></span></div>
	</div>
</nav>

</div>

</div>

<footer id="footer" class="mw-footer" role="contentinfo" >
	<ul id="footer-info">
	<li id="footer-info-lastmod"> This page was last edited on 29 March 2022, at 04:23<span class="anonymous-show">&#160;(UTC)</span>.</li>
	<li id="footer-info-copyright">Text is available under the <a rel="license" href="http://en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License 3.0</a><a rel="license" href="http://creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="http://foundation.wikimedia.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="http://foundation.wikimedia.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="http://www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
</ul>

	<ul id="footer-places">
	<li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy policy</a></li>
	<li id="footer-places-about"><a href="https://en.wikipedia.org/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
	<li id="footer-places-disclaimer"><a href="https://en.wikipedia.org/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
	<li id="footer-places-contact"><a href="http://en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
	<li id="footer-places-mobileview"><a href="http://en.m.wikipedia.org/w/index.php?title=C-Met_inhibitor&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
	<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
	<li id="footer-places-statslink"><a href="https://stats.wikimedia.org/#/en.wikipedia.org">Statistics</a></li>
	<li id="footer-places-cookiestatement"><a href="https://foundation.wikimedia.org/wiki/Cookie_statement">Cookie statement</a></li>
</ul>

	<ul id="footer-icons" class="noprint">
	<li id="footer-copyrightico"><a href="https://wikimediafoundation.org/"><img src="https://en.wikipedia.org/static/images/footer/wikimedia-button.png" srcset="/static/images/footer/wikimedia-button-1.5x.png 1.5x, /static/images/footer/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation" loading="lazy" /></a></li>
	<li id="footer-poweredbyico"><a href="https://www.mediawiki.org/"><img src="https://en.wikipedia.org/static/images/footer/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/static/images/footer/poweredby_mediawiki_132x47.png 1.5x, /static/images/footer/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></li>
</ul>

</footer>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.833","walltime":"0.975","ppvisitednodes":{"value":4192,"limit":1000000},"postexpandincludesize":{"value":200128,"limit":2097152},"templateargumentsize":{"value":4620,"limit":2097152},"expansiondepth":{"value":22,"limit":100},"expensivefunctioncount":{"value":5,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":107070,"limit":5000000},"entityaccesscount":{"value":0,"limit":400},"timingprofile":["100.00%  702.092      1 -total"," 47.52%  333.643      1 Template:Reflist"," 20.50%  143.962      6 Template:Cite_journal"," 17.11%  120.146     16 Template:Citation"," 12.92%   90.743      7 Template:Navbox"," 10.75%   75.467      2 Template:When"," 10.71%   75.196      4 Template:Update_after","  9.81%   68.899      1 Template:Drug_design","  7.65%   53.683      2 Template:Fix","  7.18%   50.394      4 Template:Update_inline_span"]},"scribunto":{"limitreport-timeusage":{"value":"0.398","limit":"10.000"},"limitreport-memusage":{"value":6716933,"limit":52428800}},"cachereport":{"origin":"mw1451","timestamp":"20220505180528","ttl":3600,"transientcontent":true}}});});</script>
<script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"C-Met inhibitor","url":"https:\/\/en.wikipedia.org\/wiki\/C-Met_inhibitor","sameAs":"http:\/\/www.wikidata.org\/entity\/Q5005894","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q5005894","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2011-09-28T12:05:35Z","dateModified":"2022-03-29T04:23:34Z","headline":"class of compounds"}</script><script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"C-Met inhibitor","url":"https:\/\/en.wikipedia.org\/wiki\/C-Met_inhibitor","sameAs":"http:\/\/www.wikidata.org\/entity\/Q5005894","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q5005894","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2011-09-28T12:05:35Z","dateModified":"2022-03-29T04:23:34Z","headline":"class of compounds"}</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":153,"wgHostname":"mw1456"});});</script>
</body>

<!-- Mirrored from en.wikipedia.org/wiki/C-Met_inhibitor by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 05 May 2022 18:32:08 GMT -->
</html>